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2. Introduction
2.1. Functional role of p97 and its cofactors
Mammalian p97 is an ubiquitously expressed member of the type II AAA (ATPase 
associated with various activities) ATPase family. Highly conserved orthologs are 
e.g. expressed in the archaebacterium Sulfobus acidocaldarius (SAV), 
Saccharomyces cerevisiae (CDC48), Dictyostelium discoideum (cdcD), Arabidopsis 
thaliana (AtCDC48), and Drosophila melanogaster (TER94) thus demonstrating that 
p97 is an essential and evolutionary highly conserved cellular protein (Moir et al., 
1982; Feiler et al., 1995; Confalonieri, et al. 1994; Pinter et al., 1998; 
Bakthavatsalam et al., 2007). The unfavourable name VCP (for valosin containing 
protein) was initially given to p97 after trying to purify the hormone peptide valosin 
but turned out to be an artefact (Koller and Brownstein, Nature 1987). p97 has a 
tripartite structure comprising an N-terminal domain (CDC 48) involved in ubiquitin 
binding, and two central D1- and D2-domains, which provide ATP binding and 
hydrolysis (DeLaBarre and Brünger, 2003). p97 assembles into functional hexamers 
with a central cylinder formed by the D-domains surrounded by the N-domains. The 
D1-domain is mainly responsible for p97 hexamerization while the D2-domain 
provides the major ATPase activity to p97 that enables it to function as a molecular 
chaperone interacting with a diverse group of adaptors to perform specific cellular 
functions (Zhang et al., 2000).
p97 has been associated with a wide variety of essential cellular processes 
comprising nuclear envelope reconstruction, the cell cycle, postmitotic Golgi 
reassembly, suppression of apoptosis, DNA damage response, the ubiquitin 
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proteasome protein degradation system and the endoplasmic reticulum associated 
protein degradation (ERAD) pathway (Kondo et al., 1997; Rabouille et al., 1998; 
Meyer et al., 2000; Hetzer et al., 2001; Ye et al., 2001; Rabinovich et al., 2002; Ye et 
al., 2004; Lilley and Ploegh, 2005).
Most, if not all of these functions seem to be directly linked to p97’s ability to bind 
(multi-)ubiquitinated proteins and to segregate them from their binding partners, or 
to extract them from protein complexes (Rape et al., 2001; Meyer et al., 2002). The 
association of p97 with substrates is still not fully understood (Jentsch and Rumpf, 
2007). In vitro binding studies indicate a direct interaction of ubiquitinated substrates 
with the N-domain of p97 (Dai and Li, 2001; Rape et al., 2001). However, the more 
common mechanism seems to be the indirect binding of p97’s N-terminal domain to 
ubiquitinated substrates mediated by cofactors (Rape et al., 2001; Meyer et al. 2002; 
Hartmann-Petersen et al., 2004; Schuberth et al., 2004; Richly et al., 2005). 
Apart from these ‘segregase’ functions, p97 seems to influence the degree of 
ubiquitination of the bound substrates (Hartmann-Petersen et al., 2004; Richly et al., 
2005). Hence, so-called ‘substrate-processing cofactors’ together with p97 can either 
promote polyubiquitination, inhibit polyubiquitination or deubiquitinate 
(multi-)ubiquitinated substrates (Koegl et al., 1999; Uchiyama et al., 2002; Burnett et 
al., 2003; Wang et al., 2004; Richly et al., 2005; Rumpf and Jentsch, 2006).
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2.2. Function of p97 in the ERAD pathway
The ubiquitin-proteasome system (UPS) is a major degradation system for short-
lived proteins (Hershko and Ciechanover, 1998). Proteins to be degraded are labeled 
with ubiquitin. Ubiquitin is conjugated through its carboxy terminus usually to 
ε-amino groups of lysine residues. This conjugation typically involves three types of 
enzyme: E1 (ubiquitin-activating enzyme) hydrolyses ATP and forms a thioester-
linked conjugate between itself and ubiquitin; E2 (ubiquitin-conjugating enzyme) 
receives ubiquitin from E1 and forms a similar thioester intermediate with ubiquitin; 
and E3 (ubiquitin ligase) binds both E2 and the substrate, and transfers the ubiquitin 
to the substrate. The ubiquitin itself can form a substrate for further rounds of 
ubiquitination, resulting in the formation of a polyubiquitin chain. Chains of four or 
more ubiquitin molecules (linked by lysines at residue 48) appear to form a 
recognition signal that allows substrates to be degraded by the 26S proteasome 
complex (Richly et al., 2005; Rubinsztein, 2006). The degradation is thus specifically 
targeted to selected proteins. Prompt removal of these proteins is critical to the 
precise and timely regulation of intracellular signaling involved in multiple cellular 
processes.
The endoplasmic reticulum-associated degradation (ERAD) pathway degrades 
initially endoplasmic reticulum (ER) localized protein substrates through the 
ubiquitin-proteasome system (Bonifacino and Weissman, 1998; Hampton, 2002). 
The ER is an intracellular membranous structure that performs such important 
functions as protein post-translational modifications, protein folding and 
oligomerization, and synthesis of lipids and sterols (Ding et al., 2007). Degradation 
prone proteins are abnormal (e.g. misfolded or misassembled) ER luminal and 
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membrane proteins as well as normal ER-resistant proteins for regulatory purposes. 
As the ubiquitin-proteasome system is absent from the ER lumen, these proteins have 
to be retrotranslocated to the cytosol or extracted from the ER membrane. p97 
together with the cofactors Ufd1 and Npl4 is required for most ERAD substrates in 
an unclear mechanism which retrotranslocates or extracts or segregates them from a 
proposed retrotranslocation channel (Bays et al., 2001; Ye et al., 2001; Jarosch et al., 
2002; Rabinovich et al., 2002; Braun et al., 2002; Elkabetz et al., 2004). Further 
general and/or specialized components like Ufd2, the homologues Rad23/Dsk2 and 
Ubx2 are involved in ERAD function (Medicherla et al., 2004; Schuberth et al., 
2004; Richly et al., 2005)
2.3. The alternative degradation system autophagy is functionally coupled 
to the UPS
Macroautophagy (referred as autophagy hereafter) is the second major intracellular 
degradation system. Unlike the UPS, autophagy is mainly responsible for the 
degradation of long-lived proteins and other cellular contents (Levine and Klionsky, 
2004; Lum et al., 2005). Autophagy starts with the formation of double-membrane-
bounded structures known as autophagosomes, or autophagic vacuoles (AVs). These 
fuse with lysosomes to form autophagolysosomes, and their contents are then 
degraded by acidic lysosomal hydrolases (Ravikumar and Rubinsztein, 2006).
Although the proteins targeted by autophagy and the UPS are different, the two 
systems serve a similar purpose in degrading proteins and recycling amino acids. 
Current studies demonstrated that the two cellular degradation systems are 
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functionally coupled and suppression of UPS activates autophagy (Brodsky and 
Scott, 2007; Ding et al., 2007; Pandey et al., 2007).
2.4. Characterization of the disease IBMPFD
Autosomal dominant inclusion body myopathy (IBM) associated with Paget disease 
of the bone (PDB) and frontotemporal dementia (FTD), or IBMPFD (OMIM 
605382), is a late-onset human multisystem disorder caused by mutations of the p97 
protein on chromosome 9p13-p12 (Watts et al., 2004; Haubenberger et al., 2005; 
Schröder et al., 2005). Apart from R191Q and A232E mutations, which reside in the 
N-D1-linker region and D1-domain, respectively, all other pathogenic mutations 
described so far are located in exons coding for the CDC48 domain of the p97 
protein (Watts et al., 2004; Haubenberger et al., 2005; Schröder et al., 2005).
Fig. 1. Domain structure of the p97 protein: 
CDC48 domain composed of double ψ barrel (amino acids 25–106, orange) and the 
four-stranded β barrel (amino acids 112–186, cyan), connected by a short linker 
region (amino acids 107-111, green). The CDC48 domain connects the 
D1-AAA-ATPase domain (amino acids 208-459, blue) by a linker region (amino 
acids 187-208, yellow). Linker region L2 (dark green), second AAA-ATPase domain 
(amino acids 481-761, D2, dark blue) and C-domain (amino acids 762-806, grey) 
are indicated. Mutations detected in our three German IBMPFD patients affect 
evolutionarily highly conserved arginine residues in codon 93 and codon 155 of the 
CDC48 domain (red) (Modified from Hübbers et al., 2007).
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A further pathogenic link of p97 to protein degradation pathways is highlighted by 
the observation that p97-positive protein aggregates have been documented in 
skeletal muscle and in neurons of the central nervous system of IBMPFD patients 
(Watts et al., 2004; Schröder et al., 2005). In neurons, these p97-positive inclusions 
are exclusively present in the nucleus, whereas in skeletal muscle only cytoplasmic 
p97-positive aggregates have been reported. However, p97-positive aggregates are 
not specific for IBMPFD and have been documented in a wide variety of 
neurodegenerative disorders comprising Parkinson’s disease, Lewy Body disease, 
Huntington’s disease, amyotrophic lateral sclerosis, and spinocerebellar ataxia 
type III (SCAIII; Machado-Joseph disease) (Hirabayashi et al., 2001; Mizuno et al., 
2003; Nan et al., 2005). p97 directly interacts with ataxin-3, the protein mutated in 
SCAIII, and recent in vivo studies using Drosophila demonstrated that p97 
selectively modulates aggregation and neurotoxicity induced by pathogenic ataxin-3 
(Böddrich et al., 2006).
2.5. Clinical observations in patients involved in this study
Clinical data and biopsy material from three German patients suffering from 
IBMPFD are included in this study (Schröder et al., 2005; Hübbers et al., Brain 
2007). Clinical investigation of patients and probes derived from these patients was 
mainly done by R. Schröder before the start of this study.
Patient I is a 74-year-old male patient with a >20-year history of slowly progressive 
distal muscle weakness predominantly affecting the lower extremities and 
progressive cognitive impairment. Neurological examination showed marked 
generalized weakness and atrophy of distal arms and leg muscles. In addition, axial 
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weakness of the lumbar trunk was noticed. Repeated neuropsychiatric evaluation 
showed evidence of progressive personality changes and cognitive decline due to 
frontotemporal brain dysfunction. Axial computed tomography revealed Paget-like 
bone changes in the right hip. Mutation analysis revealed a novel heterozygous 
nucleotide substitution from arginin to cystein in exon 3 (p.Arg93Cys) of the p97 
gene (GenBank AC004472; Hübbers et al., 2007).
Patient II was a 62-year-old female patient harbouring of a progressive proximal 
muscle weakness and frontal and temporal brain atrophy leading to a severely 
demented patient with a flaccid, predominantly proximal tetraparesis. The mother of 
the reported patient, her mother’s brother as well as one of his children suffered from 
similar medical conditions. She died of pneumonia and cardiac failure in 1998. 
Autopsy at that time showed severe generalized wasting of her skeletal muscles, but 
no signs of Paget’s disease of the bone. The total heart weight was 480 g; left 
ventricular and right ventricular wall thickness was 1.7 and 0.7 cm, respectively. 
Neurons exhibited nuclear inclusions containing p97- and ubiquitin-containing 
material. A heterozygous mutation in exon 5 leading to an amino acid substitution 
from arginine to cystein in codon 155 was identified (p.Arg155Cys; Schröder et al., 
2005). Additionally, mutations of the desmin and αB-crystallin genes were ruled out 
by direct sequence analysis in this patient. 
Patient III is a 54-year-old female. She gave a 30-year history of slowly progressive 
muscle weakness and atrophy predominantly affecting her shoulder girdle, trunk and 
distal leg muscles (Fig. 2A). Paget’s disease of the bone confined to the first lumbar 
vertebra (Fig. 2B). A detailed neuropsychological evaluation suggested mild 
frontotemporal cognitive dysfunction. Neurological examination showed severe 
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weakness and atrophy of her scapular fixator muscles (deltoid, rhomboid, supra- and 
infraspinatus) and trunk extensors. In addition, she had slight to moderate muscle 
weakness of her finger extensor, hip flexor and distal leg muscles. Whole-body MRI 
demonstrated widespread muscular involvement with pronounced signal changes in 
her erector spinae, hamstring and calf muscles (Fig. 2C, D and E). p97 mutation 
analysis of a DNA sample revealed a heterozygous nucleotide substitution causing an 
amino acid substitution in the same codon as in patient II from arginine to histidine 
(p.Arg155His).
Fig. 2. Clinical and MRI findings in Patient III. 
(A) The marked scapular winging and lumbar lordosis may be noted. (B) The sagittal 
view of the lumbar spine reveals a stripy ossification of the first lumbar vertebra 
(arrowhead) due to Paget’s disease. T1-weighted TSE-sequence with 600/12 ms 
(TR/TE), 4 mm slice-thickness. (C) The cross-cut view at the level of the thoracic 
spine demonstrates a complete fatty replacement of the erector spinae muscles (*). 
T1-weighted TSE-sequence with 450/17 ms (TR/TE), 5 mm slice-thickness. (D) The 
cross-cut view of the thighs shows a high degree of fatty degeneration of the right 
semimembranosus muscle (*) and, to a lesser degree, of the left semimembranosus 
muscle (+). T1-weighted TSE-sequence with 450/17 ms (TR/TE), 5 mm slice-
thickness. (E) MRI of the calves depicts marked fatty replacement of the left 
gastrocnemius muscle (*) as well as signal changes in the anterior compartment 
muscles (+). T1-weighted TSE-sequence with 450/17 ms (TR/TE), 5 mm slice-
thickness. (Hübbers et al., 2007)
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2.6. Scientific questions and working plan
In summary this study was initiated to answer questions regarding the pathogenesis 
of the IBMPFD disease, which was described recently. To date, information about 
the complex pathology of the IBMPFD disease and experimental data about the cell 
biology and biochemistry were limited. To illuminate mechanisms that are involved 
in the development of this late onset and ultimatively lethal disease, the following 
questions were addressed:
• What are the morphological and ultrastructural changes in the IBMPFD 
diseased striated muscle tissue?
• Does mutant p97 induce changes in its post-translational modification or 
subcellular localization?
• Can a cell culture model of the IBMPFD disease be established and do p97 
overexpressing cells exibit a phenotype similar to that of IBMPFD diseased 
tissue? Is a cell culture model capable to reproduce the formation of 
pathological protein aggregates?
• Are known pathways in which p97 is involved impaired by the p97 
mutations? Are ERAD and proteasomal degradation activities affected?
• What are the consequences of p97 mutations on the molecule structure and 
which functional conclusions can be drawn out of it?
To address these questions, a variety of histological, molecular and cell biological, 
and in silico investigations were performed.
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3. Results
3.1. Morphological, ultrastructural and biochemical analysis of the 
skeletal muscle and cardiac pathology
3.1.1. Skeletal muscle pathology
Morphological evaluation of a vastus lateralis and tibial anterior biopsy from 
Patient I showed severe degenerative changes consisting of increased fibre size 
variation, atrophy of both fibre types, presence of terminal atrophic and angulated 
fibres, hypertrophic type-1 fibres, degenerating and a few regenerating fibres, 
‘myopathic grouping’ as well as marked fatty replacement of muscle fibres and 
broadening of connective tissue (Fig. 3A). A diagnostic muscle biopsy taken from 
the biceps brachii muscle of Patient II displayed the classical myopathological 
picture of an IBM with an abundance of rimmed vacuoles (Fig. 3B). In contrast, the 
biopsy from the vastus lateralis muscle in Patient III showed only mild and 
unspecific myopathological changes consisting of type I fibre predominance, 
atrophic and hypertrophic fibres (Fig. 3C). In addition, few de- and regenerating 
fibres could be demonstrated. It is noteworthy that in biopsies from Patient I and III 
only a few fibres with rimmed vacuoles could be detected. None of the three reported 
cases showed inflammatory infiltrates.
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Fig. 3. Morphological analysis of IBMPFD muscle.
(A) Biopsy from Patient I revealed severe degenerative muscle changes. The marked 
fatty replacement of muscle fibres, broadening of connective tissue, rounding and 
atrophy of muscle fibres and hypertrophic fibres may be noted. The arrow denotes a 
hypertrophic fibre with a central rimmed vacuole. (B) Biopsy from Patient II showed 
the classical picture of an IBM with an abundance of rimmed vacuoles. (C) Biopsy 
from Patient III showed only mild and unspecific myopathological changes. Fibres 
containing rimmed vacuoles are marked by arrows. [Haematoxylin and Eosin 
staining; bars: (A) 100 µm, (B) 50 µm, (C) 60 µm].
Double-immunofluorescence analysis of skeletal muscle from Patient III revealed a 
small number of fibres (<5%) containing cytoplasmic foci of p97- and ubiquitin-
positive protein aggregates (data not shown), whereas the corresponding analysis of 
the muscle biopsy from Patient II showed a high number of fibres (30-40%) with 
single or multiple p97- and ubiquitin-positive cytoplasmic inclusions (Fig. 4A and 
B). In addition, double-staining with p97 antibody and DAPI 
(4’,6’-diamidino-2-phenylindoledihydrochloride) revealed multiple fibres with 
p97-positive nuclear inclusions (Fig. 4C and D). Further analysis revealed multiple 
fibres displaying subsarcolemmal and cytoplasmic areas with increased αB-crystallin 
(Fig. 4E) and desmin labeling (Fig. 4F).
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Fig. 4. Indirect immunofluorescence analysis of IBMPFD muscle from Patient II.
(A) p97 labeling of cytoplasmic aggregates. (B) p97 and ubiquitin
double-immunofluorescence labeling of cytoplasmic aggregates. (C) p97 labeling of 
cytoplasmic and nuclear aggregates. (D) p97 and DAPI labeling. The presence of 
cytoplasmic (red, arrow) and nuclear (pink, arrowheads) aggregates may be noted. 
(E) Pathological αB-crystallin staining with positive labeling of a giant cytoplasmic 
(*) and multiple small subsarcolemmal aggregates (arrowheads). (F) Pathological 
desmin staining in two muscle fibres displaying increased subsarcolemmal 
(arrowheads) and cytoplasmic areas (arrow) with increased desmin immunolabeling. 
Bars: (B) 70 µm, (D) 50 µm, (F) 40 µm.
A detailed ultrastructural analysis was performed on skeletal muscle from Patient II. 
The p97-positive nuclear inclusions consisted of filamentous material (Fig. 5A). In
analogy to the abundance of rimmed vacuoles and cytoplasmic p97 and 
ubiquitin-positive inclusions at the light microscopic level, many fibres contained 
autophagic vacuoles with haphazardly arranged filamentous material as well as large 
cytoplasmic areas consisting of densely or loosely packed filamentous material 
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(Fig. 5B). Multiple fibres also displayed areas with granulofilamentous material as 
seen in the group of myofibrillar myopathies (Fig. 5C). Immunogold EM showed a 
dense desmin-positive labeling of these areas (Fig. 5D). 
Fig. 5. Ultrastructural analysis of skeletal muscle from Patient II. 
(A) Filamentous nuclear inclusion (*); arrows indicate the nuclear membrane. (B) 
Cytoplasmic area with loosely and densely packed filamentous material. (C) The 
arrows denote an area with granulofilamentous material. (D) Immunogold electron 
microscopy with the monoclonal anti-desmin antibody (mab-D33) and a secondary 
antibody coupled to 10 nm gold particles showed a dense labeling of filamentous 
aggregates. Bars: (A) 0.5 µm, (B) 0.6 µm, (C) 0.7 µm, (D): 0.25 µm.
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3.1.2. Cardiac pathology 
Post-mortem analysis of the heart of Patient II revealed a marked left ventricular 
dilatation and thickening of the left ventricular wall (Fig. 6A). Histopathological 
examination showed cellular hypertrophy of myocytes and in conjunction with 
multiple small parenchymal scars in both ventricles. Immunostaining of formalin-
fixed and paraffin-embedded cardiac tissue revealed multiple cardiomyocytes 
displaying ubiquitin-positive cytoplasmic and single nuclear inclusions (Fig. 6B and 
C).
Fig. 6. Cardiac pathology in IBMPFD.
(A) Post-mortem image of the heart from Patient II displaying left ventricular 
dilatation (*) and thickening of the left ventricular wall (brace). (B and C) Ubiquitin 
immunostaining of cardiac muscle tissue. The presence of cytoplasmic (arrows) and 
intranuclear (arrowhead) ubiquitin-positive inclusions may be noted. (B and C) 
Alkaline phosphatase anti-alkaline phosphatase staining (APAP). Bars: (B) 50 µm, 
(C) 15 µm.
3.1.3. p97 protein expression in IBMPFD muscle
We performed 1D- and 2D-SDS-PAGE in conjunction with western blotting of total 
protein extracts of normal and diseased (R93C, R155H, R155C) skeletal muscle. p97 
immunoblotting after 1D-SDS-PAGE revealed a single band corresponding in size to 
97 kDa in all samples analysed without significant changes in the total amount of 
p97 between normal and R93C-, R155H-, R155C-IBMPFD muscle (Fig. 7). A 
previous study reported a shift of p97 from the soluble to the pellet fraction in 
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transient transfection experiments using p97-R155H-GFP and p97-R95G-GFP 
constructs (Weihl et al., 2006). To study the distribution of p97 between soluble and 
insoluble muscle protein fractions, we performed differential centrifugation of 
muscle tissue lysates. However, in IBMPFD and normal control muscle p97 was 
exclusively found in the pellet fraction of IBMPFD and normal control muscle (Fig.
7).
Fig. 7. p97 immunoblot analysis of normal and IBMPFD muscle after differential 
centrifugation.
Western blotting of equal amounts of total protein extracts (T), soluble (S), and pellet 
fractions (P) from normal (Control) and diseased (R155C, R155H, R93C) skeletal 
muscle after centrifugation at 100.000 x g. Desmin labeling (53 kDa) was used as an 
internal loading control. p97-immunoblotting detected a single band corresponding 
to a molecular weight of ~97 kDa in pellet and total protein fractions of all probes 
analysed.
p97 immunoblotting after 2D gel electrophoresis of total protein extracts from 
normal human skeletal muscle revealed a prominent spot at pH 5.20. In addition, a 
second spot with reduced signal intensity was detected at the position of pH 5.16, 
which corresponds well with the calculated pI 5.14. A corresponding analysis of 
diseased skeletal muscle (R155C) showed an identical pattern compared to the 
normal human control muscle (Fig. 8).
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Fig. 8. 2D gel electrophoresis followed by p97 indirect immunoblot analysis of total 
protein extracts from normal and diseased (R155) human skeletal muscle. 
A mixture of both samples was loaded as internal control to confirm that the detected 
spots of normal and diseased proteins correspond to each other.
3.1.4. Analysis of normal and IBMPFD primary human myoblasts
In order to study pathological protein aggregate formation in cultured cells, we 
analysed normal and IBMPFD (R155C-p97 mutant) primary human myoblasts. 
Immunostaining using FK2 (Fig. 9C, D) and p97 antibodies (data not shown) 
revealed an identical reticular staining pattern in normal and IBMPFD myoblasts. In 
contrast to IBMPFD muscle, no pathological protein aggregate formation could be 
detected. Even treatment with clasto-lactacystin β-lactone (irreversible 20S 
proteasome inhibitor) or MG132 (reversible 26S proteasome inhibitor) did not 
induce protein aggregates (Fig. 9E – H).
SM WT
SM R155C
SM WT+R155C
pH 5.20pH 5.16
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Fig. 9. Confocal immunofluorescence images of IBMPFD (A, C; E and G; R155C) 
and normal (B, D, F and H) primary human myoblasts.
Cells were stained with an antibody directed against poly-ubiquitin (FK2). (A and B) 
Controls lacking the primary antibody. (C and D) untreated cells, (E and F) MG132 
treated cells, (G and H) Lactacystin treated cells. Note that both normal and 
IBMPFD myoblasts display an identical reticular FK2-staining pattern without any 
evidence of FK2-positive protein aggregates in treated and untreated cells; bar, 
20 µm.
We also performed indirect immunoblotting after gel electrophoresis of untreated 
total cell lysates from these primary myoblasts (Fig. 10). p97 staining (upper pannel) 
showed equal signals for both mutated and control muscle, thus indicating that there 
is no obvious influence of the mutation on the total amount of p97 protein 
expression. Desmin (middle panel) was used to confirm the myoblast nature of the 
primary cells and as an internal loading control, respectively. β-actin (lower panel) 
was used as an additional internal loading control.
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Fig. 10. Immunoblot analysis of total protein extracts from cultured normal and 
IBMPFD (R155C-p97 mutant) primary myoblsts. 
Note the equal p97 signal intensities in samples from normal and IBMPFD 
myoblasts. Desmin was used to confirm the myoblasts nature of the primary cells and 
as an internal loading control, respectively. In addition,  β-Actin was used as an 
internal loading control.
3.2. Generation and characterization of wt and mutant p97 constructs
We generated wild type and mutant (R93C, R155C, R155H) cDNA constructs to 
study the effects of p97 protein mutants at the cellular level (Fig. 11). The following 
transfection and transduction experiments were performed: (i) Wt- and 
mutant-GFP-p97-FLAG and p97-FLAG-GFP were transiently and stably expressed 
in HEK293 cells; (ii) wt- and mutant-p97-FLAG-GFP were transiently expressed in 
C2F3 myoblasts; (iii) wt- and the R155C-p97-FLAG mutant were stably expressed in 
C2F3 myoblasts. 
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Fig. 11. Schematic representation of constructed p97 vectors. 
Upper panel: Representation of the endogenous p97 protein. Panel 2 – 4: Full length 
p97 constructs for the expression of wt, R93C, R155C, and R155H proteins were 
constructed with an additional FLAG-Tag at the C-terminus (all constructs) and a 
GFP was fused to the C-terminus (2) or N-terminus (3) for fluorescence detection. 
Lower panel: Partial p97 construct for the expression of the first 208 amino acids of 
wt, R155C and R155H protein representing the N-domain and the N-D1 linker were 
fused to a FLAG-tag.
3.2.1. Immunofluorecence analysis of p97 overexpressing cells
Transfected cells were analysed by life cell imaging and indirect 
immunofluorescence analysis after methanol or paraformaldehyde fixation. 
Expression of either wt-p97-constructs in HEK293 cells resulted in an intense 
labeling of the entire cytoplasm and, inconsistently, in a less intense nuclear signal of 
the GFP fusion proteins (Fig. 12A-O and Fig. 13A-O). All N- or C-terminally tagged 
full-length mutant p97 constructs showed the same localization as endogenous p97, 
with no evidence of abnormal cytoplasmic protein aggregate formation in HEK293 
and C2F3 cells, as it was presented earlier by Weihl et al. (2006). Transfection of 
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GFP alone yielded in a strong uniform labeling of both the cytoplasm and the 
nucleus (Fig. 12A, F, K and Fig. 13A, F, K). 
To address the issue of protein aggregate formation in a more physiological setting, 
we performed stable transfections of HEK293 and C2F3 cells. Two months after the 
initial transfection, cells were analysed by life cell imaging. The localization of the 
three p97 mutants again was indistinguishable from wt-p97, with no evidence of 
protein aggregate formation (data not shown). Triton X-100 treatment before or after 
fixation of HEK293 cells did not unmask any protein aggregates (data not shown). 
Additionally, we performed indirect immunofluorescence analysis of the transfected 
HEK293 cells using antibodies directed against p97, FLAG and poly-ubiquitinated 
proteins (FK2). Here, p97 (Fig. 12P-T and Fig. 13P-T) and FLAG (data not shown) 
labeling showed a pattern analogous to N- or C-terminally GFP- or FLAG-tagged 
wt- and mutant-p97 constructs in living and fixed cells. The FK2 antibody, a 
sensitive marker for pathological aggregates containing poly-ubiquitinated proteins, 
showed a diffuse cytoplasmic staining with occasional small foci displaying 
accentuated FK2 immunolabeling in the cytoplasm and nucleus of non-transfected 
(data not shown) as well as transfected (wt-, R93C-, R155H-, R155C-p97) HEK293 
cells (data not shown).
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Fig. 12. Confocal images of HEK293 cells stably overexpressing wt- or mutant p97 
protein fused to N-terminal GFP.
(A – E) Living cells, GFP signal; (F – J) Methanol fixation, GFP signal; (K – O) 
Paraformaldehyde fixation, GFP signal; (P-T) Indirect immunofluorescence of 
paraformaldehyde fixated cells, p97 staining. (A) GFP Vector control, (B) GFP-wt-
p97-FLAG, (C) GFP-R93C-p97-FLAG, (D) GFP-R155C-p97-FLAG, (E) GFP-
R155H-p97-FLAG. (F) GFP Vector control, (G) GFP-wt-p97-FLAG, (H) GFP-
R93C-p97-FLAG, (I) GFP-R155C-p97-FLAG, (J) GFP-R155H-p97-FLAG. (K) GFP 
Vector control, (L) GFP-wt-p97-FLAG, (M) GFP-R93C-p97-FLAG, (N) GFP-
R155C-p97-FLAG, (O) GFP-R155H-p97-FLAG, (P) p97 staining control lacking 
primary antibody, (Q) GFP-wt-p97-FLAG, (R) GFP-R93C-p97-FLAG, (S) GFP-
R155H-p97-FLAG, (T) GFP-R155C-p97-FLAG. Bar, 20 µm. 
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Fig. 13. Confocal images of HEK293 cells stably overexpressing wt- or mutant-p97 
protein fused to a C-terminal GFP.
(A – E) Living cells, GFP signal; (F – J) Methanol fixation, GFP signal; (K – O) 
Paraformaldehyde fixation, GFP signal; (P-T) Indirect immunofluorescence of 
paraformaldehyde fixated cells, p97 staining. (A) GFP Vector control, (B) wt-p97-
FLAG-GFP, (C) R93C-p97-FLAG-GFP, (D) R155C-p97-FLAG-GFP, (E) R155H-
p97-FLAG-GFP, (F) GFP Vector control, (G) wt-p97-FLAG-GFP, (H) R93C-p97-
FLAG-GFP, (I) R155C-p97-FLAG-GFP, (J) R155H-p97-FLAG-GFP, (K) GFP 
Vector control, (L) wt-p97-FLAG-GFP, (M) R93C-p97-FLAG-GFP, (N)R155C-p97-
FLAG-GFP, (O) R155H-p97-FLAG-GFP, (P) p97 staining control lacking primary 
antibody, (Q) wt-p97-FLAG-GFP, (R) R93C-p97-FLAG-GFP, (S) R155H-p97-
FLAG-GFP, (T) R155C-p97-FLAG-GFP. Bar, 20 µm.
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In order to rule out effects of the GFP-tag, we retrovirally transduced C2F3 (a 
subclone of C2C12) myoblasts using wt-p97-FLAG and R155C-p97-FLAG 
expression constructs. Anti-FLAG- (Fig. 14C and D) and anti-p97-staining (data not 
shown) revealed an intense labeling of the entire cytoplasm and, inconsistently, a less 
intense nuclear signal. Transduced C2F3 cells differentiated into myotubes showed 
the same results (Fig. 14E and F). However, neither myoblasts nor up to 6-day-old 
myotubes showed any evidence of protein aggregates.
Fig. 14. Confocal immunofluorescence images of retrovirally transduced C2F3 
myoblasts and myotubes overexpressing wt- or mutant-p97-FLAG protein. 
Cells were stained with an antibody directed against the FLAG-epitope. Controls, 
immunofluorescence images of untransduced cells (A) and of wt-p97-FLAG 
expressing myoblasts lacking the primary antibody (B). Distribution of wt-p97-FLAG 
in myoblasts (C) and differentiated myotubes (E). Localization of R155C-p97-FLAG 
in myoblasts (D) and differentiated myotubes (F); bar, 20 µm.
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The N-domain of p97 is reported to be crucial for cofactor-binding. To induce 
possible dominant negative-like effects, we also generated p97 plasmids for stable 
expression of the first 208 amino acids of the N-terminus of p97 (Fig. 11; wt, R155H 
and R155C) and analyzed HEK293 cells for possible differences in the localization 
of the wild type and mutant N-terminal peptides (Fig. 15). Indirect 
immunofluorescence analysis of paraformaldehyde fixated cells showed an intense 
labeling of the cytoplasm with no apparent differences between wt and mutant p97 
and, especially, no hints for aggregate formation.
Fig. 15. Confocal immunofluorescence images of transfected HEK293 cells 
overexpressing wt and mutant N-terminal peptide fragments of p97. 
Cells were stained with an antibody directed against the FLAG-epitope. Controls, 
immunofluorescence images of cells stained with secondary antibody only (A, C, E). 
Distribution of N208-wt-p97-FLAG (B), N208-R155H-p97-FLAG (D) and 
N208-R155C-p97-FLAG (F); bar, 20 µm
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3.2.2. 1D- and 2D SDS-PAGE followed by immunoblotting of p97 
overexpressing cells and primary myoblasts
For further biochemical analysis of our transfected HEK293 cells, we performed 
immunoblotting of total protein extracts using p97, GFP, FLAG and FK2 antibodies 
(Fig. 16). p97 immunoblotting labelled the endogenous p97 protein as well as the 
GFP–p97 fusion protein. The GFP and FLAG antibodies exclusively detected the 
respective fusion proteins. Comparison of signal intensities indicated an endogenous 
p97 to wt-, R93C-, R155H and R155C–p97 fusion protein ratio of 3:1.
Fig. 16. (Page 34) Western blot analysis of HEK293 total protein extracts from 
non-transfected and transfected cells as indicated. 
β-Actin was used as an internal loading control (lower panel). The ratio of 3:1 of 
endogenous versus GFP-fusion proteins (upper panel) may be noted. Poly-ubiquitin 
western blotting (FK2) revealed no significant differences in the pattern of 
immunolabelled proteins in all samples analyzed. Western blotting against 
FLAG-epitope and GFP-tag exclusively labelled transfected p97 proteins at 
predicted sizes.
Results
- 34 -
Immunoblotting after differential centrifugation of cell lysates showed that both the 
endogenous p97 and wt-, R93C-, R155H-, R155C–p97 fusion proteins are almost 
exclusively present in the soluble fraction (data not shown). To analyse whether 
ubiquitinated proteins accumulate in the cells expressing mutant-p97, we performed 
immunoblotting using the FK2 antibody. Here, identical patterns of poly-
ubiquitinated proteins were observed in all samples analysed (data not shown).
p97 immunoblotting after 2D gel electrophoresis of total protein extracts from 
wt-p97-FLAG and R155C-p97-FLAG transduced C2F3 myoblasts differentiated into 
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myotubes showed an identical pattern to the one in normal and IBMPFD muscle 
(Fig. 17).
SM WT
SM R155C
SM WT+R155C
C2F3 diff VCP-wt
C2F3 diff VCP-R155C
pH 5.20pH 5.16
Fig. 17. 2D gel electrophoresis and indirect p97 immunoblotting of total protein 
extracts of normal and IBMPFD skeletal muscle and differentiated C2F3 cells 
overexpressing wt and R155C p97.
The IBMPFD skeletal muscle analysis from Fig. 8 is shown for better comparability. 
A mixture of both skeletal muscle samples was loaded as internal control to confirm 
that the detected spots of normal and diseased proteins correspond to each other.
Expression of N208-p97-wt-FLAG, N208-p97-R155H-FLAG, and 
N208-p97-R155C-FLAG (predicted molecular mass: 25 kDa) was confirmed by 
western blot analysis using p97 and FLAG specific antibodies (Fig. 18). No changes 
to the full length situation were obvious.
Fig. 18. Western blot analysis of total protein extracts from non-transfected and 
transfected HEK293 cells overexpressing the N-terminal 208 amino acids. 
β-Actin was used as an internal loading control (lower panel), N-terminal peptides 
were detected by the FLAG-epitope (middle panel), endogenous p97 was detected by 
p97 antibody (upper panel).
Results
- 36 -
3.2.3. Cell proliferation assay
Cell proliferation assay showed that cells which were stably overexpressing wt-p97 
and R155C-p97 decreased the cell growth as compared to untransduced C2F3 
myoblasts or untransfected HEK293 cells. However, no significant difference had 
been found between the cells stably overexpressing wt-p97 and R155C-p97 (Fig. 19).
Fig. 19. Cell proliferation assay of untransduced and transduced C2F3 cells and 
untransfected and transfected HEK293 cells as indicated.
Overexpression of p97 leads to an approximately 1/3 decrease of proliferation in 
comparison to untransduced and untransfected cells. 1 x 106 cells were seeded 
initially, cells were counted again after 24 hours. Significance values were assigned 
using unpaired students T-Test.
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3.3. p97 response to cellular stress
3.3.1. Use of various cell stressors to induce p97 aggregates
IBMPFD patients show a severe phenotype with pathological intracellular protein 
aggregates in diseased tissues. These cellular damages occur in postmitotic cells and 
need several decades to accumulate. In transient and stable tranfection studies using 
mutated p97 constructs no protein aggregation pathology could be observed. In order 
to analyze the influence of various cell stressors, stably transfected and non-
transfected HEK293 cells were treated with mitomycin C (DNA-alkylating agent), 
UV radiation (DNA and protein cross-linking), H2O2 (oxidative stress), osmotic 
shock, wortmannin (PI3-kinase inhibitor), clasto-lactacystin β-lactone (irreversible 
20S proteasome inhibitor) or MG132 (reversible 26S proteasome inhibitor). Changes 
in the subcellular p97 distribution of stably transfected cells were only observed in 
response to MG132 treatment. In C-terminally GFP-tagged wt-p97- or R93C-, 
R155H-, R155C-p97 cells treatment with this reversible 26S proteasome inhibitor 
resulted in the formation of a single perinuclear aggregate with marked GFP signal 
intensity in most of the cells analyzed (Fig. 20G, I, K, M). However, these protein 
aggregates showed no presence of poly-ubiquinated proteins (labeling with the FK2 
antibody) (Fig. 20H, J, L, N) and they also did not exhibit F-actin cytoskeleton 
(phalloidin staining) (data not shown). Furthermore, 80% of the cells additionally 
displayed few small foci of intranuclear protein aggregates.
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Fig. 20. Confocal immunofluorescence images of HEK293 cells stably 
overexpressing wt- or mutant-p97-FLAG-GFP. 
(A-D) non-treated or (E-N) treated by MG132 (green = GFP; red = poly-ubiquitin, 
FK2-antibody). (A), wt-p97-FLAG-GFP transfected HEK293 cells stained with 
secondary antibody only. (B), untransfected HEK293 cells stained with the FK2 
antibody. (C,D), untreated cells overexpressing wt-p97-GFP, and treated HEK293 
cells expressing GFP only (E,F) did not display any protein aggregation. The use of 
MG132 resulted in the formation of marked perinuclear p97-positive aggregates 
(arrows) in wt-p97-GFP (G,H), R93C-p97-GFP (I, J), R155H-p97-GFP (K, L) and 
R155C-p97-GFP (M, N) cells. Note, that the p97-positive aggregates lack 
FK2-staining; bar, 40 ???
3.3.2. Time course of aggregate formation and clearance
In order to analyze the fate of aggregates, we examined aggregate formation and 
clearance in HEK293 cells stably overexpressing R155C-p97-FLAG-GFP and 
wt-p97-FLAG-GFP. When these cells were treated with the reversible proteasome 
inhibitor MG132, approximately 3/4 of the cells exhibited a perinuclear aggregate. 
The proteasomal inhibitor MG132 was washed away from the cells by changing the 
cell culture medium. Investigation of proteasomal activity recovered cells throughout 
the next days showed that both wt- and R155C-p97 overexpressing cells could clear 
the protein aggregates. However, there was a significant delay of protein aggregate 
clearance in HEK293 cells stably overexpressing R155C-p97-FLAG-GFP as 
compared to wt-p97-FLAG-GFP. To pinpoint the cause for delaying protein 
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aggregate clearance in mutant p97, stably transfected cells overexpressing wt-p97 
and R155C-p97 were seeded on coverslips for 12 h. Subsequently cells were 
incubated with CDK4 inhibitor (2-Bromo-12,13-dihydro-5H-indolo[2,3-a] 
pyrolo[3,4-c]carbazole-5,7(6H)-dione; Calbiochem; inhibits the cell cycle at the G1 
phase of cell division) to maintain constant number of cells for the quantitative 
analysis of aggregate degradation activity. Cells were subjected to the proteasome 
inhibitor MG132 for 16 h followed by recovering its activity. To monitor the 
proteasomal activity in different time periods, cells were collected every 12 h and 
fixated with paraformaldehyde and subsequently analysed by fluorescence 
microscopy. Protein aggregate clearance was dramatically decreased after 36 h of 
proteasomal inhibitor removal in cells stably overexpressing R155C-p97 (Fig. 21). 
Wt-p97 overexpressing cells showed approximately 4,5% remaining aggregates and 
mutant p97 overexpressing cells still contained a significantly higher level of 23,1% 
aggregates (p=0,045). 48 hrs after recovering proteasomal activity, both wt- and 
mutant p97 overexpressing cells showed a similar low level of remaining aggregates 
(3,2% vs. 3,3%), which did not further decrease in the next up to 24 hours (data not 
shown). The number of cells seeded for this experiment remained nearly constant 
throughout the experiment (data not shown). Both DMSO and CDK4 inhibitor were 
ruled out to induce aggregates or to negatively influence treated cells by 
investigating them throughout 84 h (data not shown).
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Fig. 21. Time course experiment of aggregate clearance after proteasome 
inhibition.
HEK293 cells overexpressing wt-p97-FLAG-GFP (black) and 
R155C-p97-FLAG-GFP (grey) were arrested in G1 phase of the cell cycle by 
addition of a CDK4 inhibitor throughout the whole experiment. Proteasomal activity 
was inhibited by incubation with MG132 for 16 h. Time points indicated give the 
time span after removal of the reversible proteasome inhibitor MG132. Bars show 
percentage of cells containing aggregates in relation to total amount of cells 
counted. Each experiment was performed four times independently and 10 randomly 
chosen viewing fields were counted in each experiment. The significant delay in 
aggregate clearance for mutant p97 36 h after reactivating the proteasome may be 
noted. Significance values were assigned using unpaired students T-Test.
3.4. Study of proteasome and ERAD activities
3.4.1. Proteasomal activity
p97 along with its cofactors is closely related to proteasomal activity. To examine the 
putative involvement of mutant p97 in a proteasomal dysfunction, we measured the 
peptidase activity of proteasomes from untransfected and wt-p97-FLAG-GFP and 
R155C-p97- FLAG-GFP overexpressing HEK293 cells. Cell lysates were prepared 
from untransfected and transfected cells and centrifugated at 1.000 x g. The 
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supernatant was incubated with fluorogenic peptide substrates, which are specific for 
the three major peptidase activities (N-Suc-LLVY-7-amino-4-methylcoumarin-AMC 
for chymotrypsin-like activity, Z-AAR-AMC for trypsin-like activity, and 
Z-LLE-7-AMC for caspase-like activity) (Fig. 22A). Measurements were performed 
in presence or absence of respective proteasome inhibitors (Epoxomicin, inhibits 
chymotrypsin-like activity; Adamantaneacetyl-(6-aminohexanoyl)3-(leucinyl)3-
vinyl-(methyl)-sulfone, inhibits all three major peptidase activities) which were used 
to ruled out other peptidase activities (data not shown). We found that the 
proteasomal activity had been increased in HEK293 cells stably overexpressing 
wt-p97-FLAG-GFP as compared to R155C-p97-FLAG-GFP and untransfected cells. 
However, there was a significant amount of proteasomal activity decreased in the 
case of cells stably overexpressing mutant R155C-p97-FLAG-GFP and its activity 
was lower than in untransfected cells. Also immunoblotting with anti-β-actin and 
anti-p97 confirmed that the amount of total protein and wt- and R155C-p97 was 
equal (Fig. 22B). The R155C mutation of p97 seems to inhibit the overall 
proteasomal activity. This finding will be further investigated using transfected 
myoblasts and primary myoblasts as well as samples of skeletal muscle biopsies 
derived from the IBMPFD patients. 
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Fig. 22. Analysis of proteasomal activity of untransfected and transfected HEK293 
cells overexpressing wt- and R155C-p97-FLAG-GFP.
(A) Cell lysates of untransfected HEK293 cells (black), stably transfected HEK293 
cells overexpressing wt-p97-FLAG-GFP (grey) and R155C-p97-FLAG-GFP (white) 
were incubated with synthetic, fluorogenic proteasome substrates 
(N-Suc-LLVY-7-amino-4-methylcoumarin-AMC for chymotrypsin-like activity, 
Z-AAR-AMC for trypsin-like activity and Z-LLE-7-AMC for caspase-like activity). 
Cells were counted and normalized before extracting proteasome-fractions and total 
protein amounts of these fractions were determined by Bradford assay and adjusted 
to equal amounts. Significance values were assigned using unpaired students T-Test. 
Note the significant decrease of proteasomal activity in cells overexpressing the p97 
mutant. (B) In addition, immunoblotting of β-actin was performed as internal 
loading control (lower panel). Also shown is the p97 indirect immunoblotting of cell 
lysates.
3.4.2. Defects in ERAD activity in the presence of mutated p97
The HMG-CoA reductase (HMGR) is the rate-limiting enzyme in cholesterol 
synthesis and thus is regulated to control cellular cholesterol levels. HMGR and other 
components of this pathway are regulated by the ERAD pathway. When cholesterol 
concentrations are low in a cell, HMGR is stabilized, because the mediator for its 
degradation, the ER resistant protein Insig-1 (insulin-induced gene 1), is degraded 
itself (Gong et al., 2006; Gong et al., 2006; Lee et al., 2006). The interaction of 
Insig-1 with HMGR (and Scap, see below) is sterol-dependent (Sun et al., 2005). For 
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HMGR stabilizing, Insig-1 is poly-ubiquitinated through the ubiquitin ligase gp78 
(also named AMFR, autocrine motility factor receptor) in combination with p97 and 
subsequently directed to the proteasome for degradation (Gong et al., 2006; Lee et 
al., 2006). In addition, a complex of SREBP (sterol regulatory element-binding 
protein) and SCAP (SREBP-cleavage-activating protein) is formed and translocated 
to the Golgi, where proteolytic activation of SREBP occurs (Edwards et al., 2000; 
Goldstein et al., 2006). This translocation is driven by the interaction of the COPII 
coat proteins Sar1, Sec23 and Sec24 with SCAP/SREBP (Sun et al., 2005). Activated 
SREBPs can now induce expression of their target genes, including HMGR and 
Insig-1 (Edwards et al., 2000; Goldstein et al., 2006).
The interaction of these components changes, when cellular cholesterol levels are 
high. Now HMGR has to be degraded, which is induced by its poly-ubiquitination 
followed by proteasomal degradation. Interestingly, ubiquitination of HMGR is 
stimulated better by sterol intermediates like lanosterol (the first sterol intermediate 
in cholesterol synthesis) and other sterol-derivates than by cholesterol itself, which, 
in contrast, better stimulate the interaction of SREBPs (Song et al., 2005; 
Bengoechea-Alonso and Ericsson, 2007). Insig-1 has to mediate the interaction of 
gp78 and p97 with HMGR in a sterol-intermediate dependent manner (Song et al., 
2005; Song et al., 2005). Also, the synthesis of HMGR has to be downregulated. This 
is done by retention of SCAP/SREBP in the ER through the formation of a stable 
complex of - once more - Insig-1 and SCAP/SREBP (Bengoechea-Alonso and 
Ericsson, 2007).
The involvement of p97 in cholesterol homeostasis and the finding of a putative 
binding pocket for a cholesterol like compound (see below) suggests a potential link 
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to a missregulated ERAD activity (Hübbers et al., 2007). Therefore we analyzed total 
cell lysates of HEK293 cells overexpressing wt-p97-FLAG-GFP and 
R155C-p97-FLAG-GFP along with untransfected HEK293 cells by immunoblotting 
with specific regard to selected compounds of the cholesterol homeostasis pathway. 
Lysates derived from untreated cells, from cells after 16 hours of incubation with the 
MG132 proteasome inhibitor, and after 36 hours of regeneration (the timepoint with 
the most significant difference in aggregate numbers, see chapter 3.3.2) were 
analyszed. Possible influences of different proliferation rates were ruled out by 
arresting the cell cycle in G1 phase while treating with a CDK4-Inhibitor. p97 
immunoblotting revealed no significant differences in its signal intensities. However, 
bands corresponding to degraded p97 protein were detected consistently in stress 
experiments (Fig. 23). The protein expression level of the p97 interacting protein 
Ufd1 was significantly decreased in cells overexpressing the R155C-p97 mutant. 
Furthermore, staining for poly-ubiquitin showed significant differences for 
R155C-p97-FLAG-GFP compared to the untransfected and wt-p97-FLAG-GFP 
overexpressing cells. These differences are obvious throughout the whole experiment 
and predominantly affected the total pattern of poly-ubiquitination 36 h after removal 
of MG132. HMG-CoA reductase is equally expressed for untransfected cells in all 
cases analysed. Wt-p97-FLAG-GFP overexpressing cells showed a HMGR signal 
similar in intensity compared to the untransfected cells, but the signal disappears 
36 h after MG132 removal. Strikingly, the HMGR signal is absent for 
R155C-p97-FLAG-GFP overexpressing cells throughout the whole experiment. The 
COPII coat protein Sec24 is solely expressed in wt-p97-FLAG-GFP overexpressing 
cells 36 h after MG132 removal. SCAP showed a decrease in signal intensity for 
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R155C-p97-FLAG-GFP overexpressing cells after aggregate induction by MG132 
treatment and during regeneration. 
The cholesterol level regulating pathway is an example where several components 
are specifically degraded through ERAD with p97 being a central component of the 
latter (Goldstein et al., 2006). Mutated p97 may exert a specific defect in interaction 
with one ore more component(s) of this pathway and thus disrupting this specific 
ERAD function.
Fig. 23. (Page 46) Western blot analysis of p97 and several ERAD and cholesterol 
homeostasis pathway associated proteins. 
Total protein extracts from non-transfected and transfected HEK293 cells 
overexpressing wt-p97-FLAG-GFP and R155C-p97-FLAG-GFP were loaded for 
Western blotting as indicated. Cells were treated with CDK4 throughout the 
experiment. Cell lysates were analyzed directly after CDK4 treatment, 16 h after 
MG132 incubation and 36 h after removal of MG132. p97 shows degraded protein 
bands for both overexpressing cell lines under stress conditions. HMG-CoA 
reductase is absent in mutant p97 overexpressing cells at both timepoints and SCAP 
is downregulated for mutant p97 under stress conditions. Ufd1 levels were equal at 
all times but decreased for mutant p97 during regeneration. Sec24 showed a single 
band for wt-p97-FLAG-GFP during regeneration. The pattern of poly-ubiquitinated 
proteins is modified for mutant p97. β-Actin stainings were used as internal loading 
controls (lower panel; after p97 blot; loading controls of other blots not shown).
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3.4.3. Fluorescence protease protection assay analysis of ER and Golgi 
morphology
To elucidate possible morphological changes of the ER and Golgi structures due to 
mutant p97 or any changes in localization of wt and mutant p97 at these organelles, 
we performed a fluorescence protease protection (FPP) assay (Lorenz et al., 2006). 
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We therefore co-transfected marker proteins into our stably transfected HEK293 
cells overexpressing wt-p97-FLAG-GFP and R155C-p97-FLAG-GFP. For ER 
staining we used pDsRed2-ER vector (Clontech No. 632409), which uses the ER 
targeting sequence of calreticulin fused N-terminally to the fluorochrome as well as 
the KDL ER retention sequence at the C-terminus of the fluorochrome. As a Golgi 
marker we used pDsRed-Monomer-Golgi (Clontech No. 632480), which uses the 
N-terminal 81 amino acids of human beta-1,4-galactosyltransferase comprising the 
membrane anchoring signal peptide of 1,4-GT fused to a C-terminal fluorochrome. 
The fusion protein is therefore directed to the transmedial region of the Golgi 
apparatus.
24 hours after transfection, both ER- and Golgi-markers showed an intense labeling 
and a typical distribution for these organelles with no differences between wt and 
mutant p97 (Fig. 24E, F, K, L, Q, R and Fig. 25E, F, K, L, Q, R). Thus, to remove 
free cytoplasmic p97-GFP and to demask possible differences in the enrichment of 
p97-GFP in these organelles, we incubated cells with 20 µM digitonin for 1 minute 
followed by 4 mM trypsin for 5 minutes. The fluorescence signals of the ER and 
Golgi markers which were not affected by this treatment were compared to the 
remaining non-cytoplasmic p97 signals. The Golgi marker did not present a co-
localization with p97 (Fig. 24O and U) while the ER marker exhibited a partial 
co-localization with p97, however, without differences between wt- and R155C-p97 
(Fig. 25O and U). Expression of the mutant p97 did not change the morphology of 
the ER or Golgi apparatus.
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Fig. 24. (Page 48) Fluorescence protease protection assay of the Golgi apparatus.
Confocal images of HEK293 cells stably overexpressing wt- or R155C-p97-
FLAG-GFP protein. In addition, a Golgi marker fused to an N-terminal pDsRed-
Monomer vector was transiently transfected. All cells were fixed using 
paraformaldehyde. Treated cells were incubated with 20 µM digitonin for 1 minute 
followed by 4 mM trypsin for 5 minutes before fixation. 
(A – C) Empty vector control, (A) GFP signal, (B) vector signal, (C) vector after 
digitonin / trypsin incubation followed by fixation. (D – I) p97 untransfected 
HEK293 cells transiently expressing Golgi marker. (D – F) fixation only, (G – I) 
after digitonin / trypsin treatment. (D, G) GFP signal, (E, H) Golgi marker, (F, I) 
merge. (J – O) cells stably overexpressing wt-p97-FLAG-GFP and transiently 
pDsRed-Monomer-Golgi, (J – L) fixation only, (M – O) digitonin / trypsin 
incubation. (J, M) wt-p97, (K, N) Golgi marker, (L, O) merge. (P – U) cells stably 
overexpressing R155C-p97-FLAG-GFP and transiently pDsRed-Monomer-Golgi, (P 
– R) fixation only, (S – U) fixation after digitonin / trypsin incubation. (P, S) R155C-
p97, (Q, T) Golgi marker, (R, U) merge. Bar, 20 µM.
Fig. 25. (Page 50) Fluorescence protease protection assay of the Endoplasmic 
reticulum
Confocal images of HEK293 cells stably overexpressing wt- or R155C-p97-FLAG-
GFP protein. In addition, an ER marker fused to an N-terminal pDsRed2 vector was 
transiently transfected. All cells were fixed using paraformaldehyde. Treated cells 
were incubated with 20 µM digitonin for 1 minute followed by 4 mM trypsin for 
5 minutes before fixation.
(A – C) Empty vector control, (A) GFP signal, (B) vector signal, (C) vector after 
digitonin / trypsin incubation followed by fixation. (D – I) p97 untransfected 
HEK293 cells transiently expressing ER marker. (D – F) fixation only, (G – I) after 
digitonin / trypsin treatment. (D, G) GFP signal, (E, H) ER marker, (F, I) merge. (J –
O) cells stably overexpressing wt-p97-FLAG-GFP and transiently pDsRed-ER, (J –
L) fixation only, (M – O) digitonin / trypsin incubation. (J, M) wt-p97, (K, N) ER 
marker, (L, O) merge. (P – U) cells stably overexpressing R155C-p97-FLAG-GFP 
and transiently pDsRed-ER, (P – R) fixation only, (S – U) fixation after digitonin / 
trypsin incubation. (P, S) p97-R155C, (Q, T) ER marker, (R, U) merge. Colocalizing 
p97 and ER-marker is indicated by arrowheads in the merges, respectively. Bar, 
20 µM.
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3.4.4. Fluorescence protease protection assay of autohagosomes 
The two major cellular protein degradation systems, the ubiquitin-proteasome system 
and the autophagy machinery are functionally coupled (Ding et al., 2007; Pandey et 
al., 2007). Downregulation of UPS results in an upregulation of autophagy. We 
therefore analyzed autophagic activity in our wt and mutant p97 overexpressing 
HEK293 cells. GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) is established 
as a marker for autophagosomes (Lorenz et al., 2006). GAPDH is an ubiquitously 
and strongly expressed cytosolic protein, which is randomly degraded through 
autophagy as many other proteins, too, and thus can be used as a marker for 
autophagic vacuoles. We used the GAPDH sequence of a commercially available 
GAPDH-CFP vector (GeneCopoeia, USA) and cloned it C-terminally to a pDsRed2 
vector. 
Both untransfected and wt-p97-FLAG-GFP overexpressing HEK293 cells showed a 
strong cytoplasmic staining for GAPDH (Fig. 26E and K). After treatment with 
digitonin and trypsin almost all GAPDH is washed out of the cell (Fig. 26H and N). 
The remaining spots of GAPDH perfectly colocalize with spots in the wt-p97 signal 
(Fig. 26N). R155C—p97-FLAG-GFP overexpressing HEK293 cells on the other 
hand show a less intense GAPDH signal compared to the wt situation in untreated 
cells. Digitonin and trypsin treatment at least unmasks a marked increase in 
remaining GAPDH spots, which also colocalise with the p97 signal. This finding 
indicates an upregulation of autophagy in mutated p97. We therefore can conclude 
that significant downregulation of proteasomal activity in R155C mutant HEK293 
cells also results in a predicted upregulation of autophagy. The decreased amount of 
cytosolic GAPDH therefore could well be a result of an increased overturn of 
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cytosolic proteins. The colocalisation of p97 with the autophagosomes implicates 
two possibilitys. On the one hand p97 could simply be degraded by the 
autophagosomes. On the other hand p97 has a functional role in the autophagy 
pathway. This issue has to be further investigated.
Fig. 26. (Page 53) Fluorescence protease protection assay of autophagosomes
Confocal images of HEK293 cells stably overexpressing wt- or 
R155C-p97-FLAG-GFP protein. In addition, GAPDH fused to an N-terminal 
pDsRed2 vector was transiently transfected. All cells were fixed using 
paraformaldehyde. Treated cells were incubated with 20 µM digitonin for 1 minute 
followed by 4 mM trypsin for 5 minutes before fixation. 
(A – C) Empty vector control, (A) GFP signal, (B) vector signal, (C) vector after 
digitonin / trypsin incubation followed by fixation. (D – I) p97 untransfected 
HEK293 cells transiently expressing GAPDH marker. (D – F) fixation only, (G – I) 
after digitonin / trypsin treatment. (D, G) GFP signal, (E, H) GAPDH marker, (F, I) 
merge. (J – O) cells stably overexpressing wt-p97-FLAG-GFP and transiently 
pDsRed-GAPDH, (J – L) fixation only, (M – O) digitonin / trypsin incubation. (J, M) 
p97-wt, (K, N) GAPDH marker, (L, O) merge. (P – U) cells stably overexpressing 
R155C-p97-FLAG-GFP and transiently pDsRed-GAPDH, (P – R) fixation only, (S –
U) fixation after digitonin / trypsin incubation. (P, S) p97-R155C, (Q, T) GAPDH 
marker, (R, U) merge. Arrowheads shown in the merges mark partiel colocalization 
of  p97 and GAPDH, respectively. Bar, 20 µM.
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3.5. Filter assay combined with GC/MS analysis of putative ligands 
binding to recombinant p97
In collaboration with A. Hofmann (Brisbane, Australia) we studied wt and mutated 
p97 in an in silico approach (Hübbers et al., 2007). Therefore the R93C, R155H and 
R155C mutations were introduced into a human p97 protein model derived from the 
murine p97 crystal structure. Analysis indicates that R93 and R155 are surface-
accessible residues located in the center of cavities that may enable ligand binding in 
both the monomeric as well as the hexameric state of p97. These cavities may be 
putative ligand-binding sites. To find potential ligands for the two putative R93 and 
R155 ligand-binding pockets, the automated docking programme LIDAEUS was 
used to screen a small-molecule database for potential ligands. For the R155C cavity, 
a steroid (16α-hydroxypregnenolone; Sigma H8252; SPH1-005-061) as well as a 
hexose-like compound (N-acetyl-α-D glucosamine-1-phosphate disodium salt; 
Sigma A2142;SPH1-000-376) could be identified. For the R93 pocket screening 
resulted in the cyclic sugars α-D-glucose-1-phosphate disodium salt (Sigma G7000; 
SPH1-004-510) and α-D-galacturonic acid-1-phosphate lithium salt (Sigma G4884; 
SPH1-004-402).
To verify a binding of these ligands, we performed a filter assay with purified 
recombinant p97-wt, p97-R93C, p97-R155C and p97-R155H. Since an interaction of 
p97 with the cholesterol homeostasis pathway is well established and many 
components in this pathway interact in a sterol-dependent manner, we first focused 
on the cholesterol derivate 16α-Hydroxypregnenolone as well as the structurally 
closely related 25-Hydroxycholesterol. Therefore we incubated the recombinant 
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proteins with 100x molar excess of the cholesterols. After removal of unbound 
cholesterol molecules by centrifugation through a Millipore Ultrafree-MC NMWL 
10.000 Biomax 10 filter (Millipore, Germany), ligands that may have bound to the 
recombinant p97 should be immobilized on the membrane. Bound ligands were 
eluted with 0,1% trifluoro acetic acid (TFA) in PBS. In collaboration with another 
group in our institute (F. G. Hanisch) the potential ligands were analysed by gas 
chromatography coupled to mass spectrometry. Unfortunately, none of the both 
ligands was detected to bind to the recombinant p97. Although this GC/MS method 
is extremely sensitive (femtomolar concentrations can be detected), ligands with low 
affinity to p97 may not be detected. As our structural analysis indicated, the 
formation of p97 homohexamers is important for ligand binding. This 
hexamerisation was intensively studied for p97-wt and p97-R155H by Weihl et al. 
(2006) and the hexamers are reported to elute exclusively from a size exclusion 
column for both recombinant wt and mutant p97. Thus, the absence of the 
compounds in our analysis could be more due to a weak interaction of p97 and its 
ligands than due to a disrupted homohexamere formation. We therefore plan to test 
possible interactions employing isothermal calorimetry.
3.6. Generation of a R155C-p97 mouse knock-in targeting vector
Further investigations of human IBMPFD tissue are restrained by the very limited 
amount of biopsy material available. Furthermore, this biopsy material mostly 
reflects very late stages of the progressive pathology. Genetic mouse models are 
powerful tools for investigating a disease relevant protein in the context of a complex 
organism and throughout all stages of the disease. Thus, we decided to generate a 
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R155C-p97 knock-in mouse. The particular R155C mutation was chosen because it 
showed the most severe phenotype in patients.
The murine p97 gene is located on chromosome 4 and consists of 17 exons spanning 
over approximately 30 kb. Murine and human p97 proteins share 99.5% identity with 
Ile206 being Val in the mouse protein. Residue R155 is coded by the first bases of 
exon 5. The homology arms of the targeting vector and the cDNA fragments to be 
used as southern probes have been amplified by PCR using BAC-clones 
RPCI23-124L1 and RPCI24-186I11 as templates. The R155C-p97 mutation was 
introduced by in vitro mutagenesis. The targeting vector was verified by restriction 
digestion and sequencing (data not shown), the southern probes have been tested 
with wild type ES-cell DNA (data not shown). 
Figure 27 demonstrates a simplified scheme indicating important aspects of the 
targeting vector, targeting locus, and restriction enzymes and fragments for the 
identification of homologous recombination. The resistance cassette for selection of 
positive ES-cell clones is positioned between exons 4 and 5 without disturbing 
conserved intron structures. The neomycin resistance is flanked by loxP sites 
allowing its deletion by a transient expression of Cre-recombinase. Neomycin gene 
and flanking loxP-sites have the same orientation as the p97 gene. Removal of the 
neomycin cassette preserves the original length and structure of the p97-mRNA. This 
targeting strategy of the murine genome leads to a genetic state with one wild type 
and one mutated p97 allele as identified in human IBMPFD patients. The R155C-p97 
knock-in vector will be used for the generation of the first p97 knock-in mouse 
available subsequent to this work.
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Fig. 27. Scheme of the R155C-p97-targeting vector and the targeted p97 gene 
locus.
The p97 intron sequence between exons 4 and 5 was replaced by the neomycin 
resistance gene (neo) flanked by two loxP-sites. The location of the 5’ and 3’ probes 
for Southern blot analysis are indicated. For the 5’ probe, upon KpnI digestion the 
wild type and deleted allele yield fragments of 16,3 and 7,1 kb, respectively; upon 
EcoRV digestion the wild type and deleted allele yield fragments of 7,1 and 9,2 kb, 
respectively. For the 3’ probe, upon EcoRI digestion the wild type and deleted allele 
yield fragments of 10,5 and 12,6 kb, respectively; upon EcoRI digestion the wild type 
and deleted allele yield fragments of 14,7 and 10 kb, respectively, and upon NciI 
digestion the wild type and deleted allele yield fragments of 18,7 and 9,7 kb, 
respectively.
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4. Discussion
4.1. Clinical phenotype
Our histopathological analysis revealed a broad spectrum of pathological changes in 
muscle reflecting different stages of disease progression in our three IBMPFD 
patients. Immunostaining using p97 antibodies demonstrated the presence of 
p97-positive cytoplasmic aggregates, a phenomenon previously described (Watts et 
al., 2004). Our analysis demonstrated that these p97-positive aggregates also display 
positive ubiquitin staining. As a further novel finding we demonstrated the presence 
of p97- and ubiquitin-positive nuclear inclusions in muscle. This aspect mirrors the 
brain pathology in IBMPFD, which is characterized by the presence of p97- and 
ubiquitin-positive nuclear inclusions in neurons (Schröder et al., 2005). Our 
ultrastructural analysis demonstrated that both the cytoplasmic and the nuclear 
inclusions in IBMPFD muscle were composed of haphazardly arranged filaments. In 
analogy to the aberrant desmin immunofluorescence staining, our ultrastructural 
studies revealed the presence of desmin-positive granulofilamentous material, the 
characteristic ultrastructural hallmark of primary desminopathies and myofibrillar 
myopathies (Schröder et al., 2003; Selcen et al., 2004; Bär et al. 2005). This finding 
indicates that, at least in advanced degenerative stages of IBMPFD, p97 mutations 
induce secondary alterations of the extrasarcomeric desmin cytoskeleton.
The post-mortem analysis of patient II revealed a novel clinical aspect in IBMPFD. 
p97 mutations not only affect skeletal muscle, but may also lead to a dilatative 
cardiomyopathy characterized by ubiquitin-positive cytoplasmic aggregates and 
nuclear inclusions. 
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4.2. Analysis of the p97 protein expression and localization 
Our immunoblotting analyses revealed no significant differences in the total amount, 
subcellular distribution and posttranslational modifications of p97 protein between 
normal and diseased muscle. In contrast to IBMPFD muscle, where endogenous p97 
is solely present in the insoluble fraction, western blot analysis of transfected cells 
(wt- and mutant-p97) demonstrated that endogenous and transfected p97 is 
predominately present in the soluble protein fraction. 
Neither morphology nor p97 distribution were affected in our cell culture 
experiments using primary myoblasts derived from patient muscle biopsy and 
HEK293 and C2F3 cells overexpressing wt or mutant p97. In addition we performed 
functional studies on these cells. Overexpression of p97 in HEK293 and C2F3 cells 
reduced proliferation rates, however without any difference between wt and mutant 
p97, as it has been reported earlier (Zhang et al., 1999). In contrast to 
IBMPFD-muscle, all our transient and stable transfection experiments using mutant-
and wt-p97 did not lead to cytoplasmic or nuclear protein aggregate formation. Only 
treatment of HEK293 cells with the proteasome inhibitor MG132 led to the 
formation of pathological protein aggregates. Aggresome formation by proteasome 
inhibitors in HEK293 cells have previously been described by Meriin et al. (1998). 
Again, no apparent differences in the extent or subcellular localization of the protein 
aggregates could be detected. Various other cell stress experiments like treatment 
with mitomycin C, UV radiation, H2O2, osmotic shock, wortmannin, and clasto-
lactacystin β-lactone as well as the use of differentiated C2F3 myotubes did not 
provide evidence for abnormal protein aggregate formation.
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These findings are in contrast to the recently published study by Weihl et al. (2006), 
who described large perinuclear aggregates in up to 33% of cells transfected with 
R155H-p97-GFP and R95G-p97-GFP, and in 7% of cells transfected with 
wt-p97-GFP. These aggregates were reported to contain poly-ubiquitinated proteins, 
a subgroup also mutated p97 protein. A potential cause for aggregates in such 
transient transfection experiments may be strong overexpression of the transfected 
gene. This is strongly supported by the following reasons: i) A previous study by Ye 
et al. (2004) demonstrated strikingly similar perinuclear aggregates in double 
transient transfection studies using His-wt-p97 and Myc-wt-VIMP, a membrane 
protein that recruits the p97-ATPase. ii) In our immunoblot-controlled stable 
transfections a ratio of 1:3 of mutant-p97 to wt-p97 did not lead to protein aggregate 
formation. iii) In primary human myoblasts derived from IBMPFD skeletal muscle, 
which most closely represent the physiological situation with one wt and one 
mutated p97 allele, no abnormal protein aggregation was detected by p97 and FK2 
immunostaining. iv) In the vast majority of IBMPFD patients, it takes at least 40 to 
50 years until the disease manifests and protein aggregates are exclusively found in 
post-mitotic cells (neurons, striated muscle cells). 
4.3. Structural analysis of wild type p97 versus R93 and R155 mutant p97
All three p97 mutations identified in our IBMPFD patients concern evolutionarily 
highly conserved arginine residues in the CDC48 domain of the p97 protein (Fig. 1).
In the light of a previous study showing that p97 mutations impair ERAD (Weihl et 
al. 2006), the binding of recombinant p97 to various ERAD-p97-co-factors and other 
known ligands was studied in collaboration with A. Böddrich (Berlin) (Hübbers et 
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al., 2007). The GST pull-down assays demonstrated that wt-p97 as well as all three 
p97 mutants showed identical binding to Ufd1- (Fig. 28), Npl4- and ataxin-3 (data 
not shown). 
Fig. 28. GST pull-down experiments with purified MBP-Ufd1. 
GST-p97 fusion proteins were bound to glutathione agarose beads and incubated 
with MBP-Ufd1. After extensive washing of the beads, bound protein was detected by 
immunoblotting using an anti-Ufd1 antibody (bottom panel). Ten per cent of the 
input binding mixture was subjected to immunoblot analysis with anti-Ufd1 (top 
panel) and anti-GST antibody (middle panel). (Hübbers et al., 2007)
With regard to protein aggregate formation, it was tested whether purified wild type 
and mutant p97 can form SDS-insoluble aggregates in vitro using a filter retardation 
assay (Wanker et al., 1999). These experiments showed that neither mutant p97 nor 
wild type p97 formed SDS-insoluble aggregates in vitro (Hübbers et al., 2007). 
Furthermore, in a previous study, the ATPase-activity of purified R155H-p97 was 
similar to the one reported for wt-p97 (Weihl et al., 2006). These results imply that 
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the various p97 mutants analyzed so far are not associated with gross alterations in 
p97 binding to known cofactors and its intrinsic ATPase enzyme activity. This favors 
the hypothesis that IBMPFD pathology is due to a toxic gain of p97 function.
To address the pathological consequences of p97 mutations at the structural level, the 
R93C, R155H and R155C mutations were introduced into a human p97 protein 
model derived from the murine p97 crystal structure, done in collaboration with A. 
Hofman (Hübbers et al., 2007). The analysis indicates that R93 and R155 are 
surface-accessible residues located in the center of cavities that may enable ligand 
binding (Fig 29). Both R93 and R155 are also surface accessible in the hexameric 
state of p97 (data not shown).
While the cleft around R155 is larger and predominantly negatively charged 
(Fig. 29B), the cavity around R93 appears smaller and rather positively charged 
(Fig. 29C). The particular shape and charge distribution within the clefts around R93 
and R155 indicate that these may be putative ligand-binding sites.
Fig. 29. (Page 63) Transparent Connolly surface with ribbon backbone of the 
human p97 model. 
The bound ADP in the D1-nucleotide-binding site is shown as Corey, Pauling, 
Koltun colouring scheme. The locations of the clefts around R93 and R155 are 
indicated by blue coloring of the surface of the two arginine residues; prepared with 
InsightII. (C and D) GRASP (Nicholls et al., 1993) surface representations coloured 
by electrostatic surface potential (red: negative, blue: positive). Shown are the clefts 
around R155 (C), as well as R93 (D). Wt R155 and R93 are represented on the left, 
while mutant R155C and R93C are shown on the right (Hübbers et al., 2007).
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Further analysis revealed that R93 maintains interactions with amino acid residues 
E194 and R65, as well as with the backbone carbonyl group of N90. These 
interactions are all within the cleft around R93. The R93C mutation leads to a loss of 
these contacts due to the shorter side chain of cystein.
In contrast, R155 interacts with amino acid residue N387 residing in the D1-domain, 
which binds and hydrolyses ATP. The N- and D1-domains are spatially separated 
and form only three direct contacts, R155-N387, R89-E261 and E30K217. The 
mutations R155C and R155H lack the interaction with N387 owing to the shorter 
amino acid side chains and thus may alter the relative orientation of the N- and 
D1-domains of p97. 
DeLaBarre and Brünger (2003) proposed a model where the mobile state of the 
N-domain is triggered by release of a latch provided by the D1α-domain. Three pairs 
of residues can be identified that could act as latch. Importantly, one of these pairs is 
R155-N387. A p97 mutant with an impaired ability to lock the N-domain is very 
likely to have lost its regulatory properties. R93 maintains interactions with amino 
acid residues E194 and R65, as well as with the backbone carbonyl group of N90. 
A B
C
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The R93C mutation leads to a loss of these contacts due to the shorter side chain of 
cystein. 
4.3.1. In silico screening of small ligand binding
Since our biochemical analysis did not reveal any detectable changes in the binding 
of wt-p97 versus mutant-p97 to known p97 ligands, a small-molecule database was 
screened in collaboration with A. Hofman for potential ligands for the two putative 
R93 and R155 ligand-binding pockets using the automated docking programme 
LIDAEUS (Hübbers et al., 2007). LIDAEUS generates sitepoints in the binding 
pockets and aims to find and dock ligands matching the pockets by chemical and 
shape complementation. The conformations are ranked according to various energy 
scores including hydrophobic interactions, and van der Waals and H-bonding (Wu et 
al., 2003). From the database comprising around 10,000 molecules, interesting 
ligands were picked for further analysis based on visual screening of the fit to the 
pocket and the LIDAEUS scoring.
The negatively charged R155 site is located at the interface between the N- and 
D1-domains. The virtual screening approach considering docking and chemical 
interaction indicated that ADP/ATP are unlikely binding partners for the R155 site, 
but identified a steroid (16α-hydroxypregnenolone; Sigma H8252; SPH1-005-061) 
as well as a hexose-like compound (N-acetyl-α-D-glucosamine-1-phosphate 
disodium salt; Sigma A2142; SPH1-000-376) as ligands with significantly higher 
binding scores than all other target screened compounds (Fig. 30A). 
Although the R155 pocket is not a typical steroid binding pocket (Tanenbaum et al., 
1998; Williams and Sigler, 1998; Bledsoe et al., 2002; Li et al., 2005), some of the 
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p97:SPH1-005-061 interacting residues are analogous to the amino acid–steroid 
contacts made by the steroid receptors.
The R93 pocket is composed of residues from the N-D1-linker region and some 
residues from the surface of the N-domain. The amino acid residues of the linker 
region constitute the top of the pocket. Thus, movement of the linker would not 
destroy the binding site, but make it more flexible. LIDAEUS screening yielded a 
number of putative target molecules. The highest scoring compounds were the cyclic 
sugars (α-D-glucose-1-phosphate disodium salt; Sigma G7000; SPH1-004-510 and 
α-D-galacturonic acid-1-phosphate lithium salt; Sigma G4884; SPH1-004-402) 
(Fig. 30B).
Fig. 30. Selected putative lead compounds suggested by LIDAEUS and confirmed 
by visual inspection of the docked ligands in the R155 (A) and R93 (B) pocket.
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The appearance of sugar-like and cholesterol like compounds for the R93 and R155 
sites establishs a link to the reported interactions between p97 and SCF(Fbs1,2), a 
cytosolic ubiquitinase for glycoproteins and gp78 (also named AMFR, autocrine 
motility factor receptor), an ER membrane resistant ubiquitin ligase and 
deglycosidase (Fang et al., 2001; Ye et al., 2005; Yoshida et al., 2005). Furthermore, 
p97 is reported to control N-glycosylation in the ER (Lass et al., 2007). Interestingly, 
mutation of UDP-N-acetylglucosamin 2-epimerase/N-acetylmannosaminase is 
reported to causes IBM (Eisenberg et al., 2001; Kayashima et al. 2002). Here, it is 
tempting to speculate that p97 mutations interfere with the binding to carbohydrates 
from misfolded glycoproteins in the endoplasmic reticulum and cytosol and with 
cholesterol derivates (Spiro, 2002; Goldstein et al., 2006; Hübbers et al., 2007).
4.4. Analysis of proteasome and ERAD activity
As the R155C-p97 mutation showed the most severe phenotype in our patients, we 
focused on this mutation. Having demonstrated that MG132-dependend inhibition of 
the proteasomal activity leads to the formation of similar amounts of protein 
aggregates in HEK293 cells overexpressing wt- and R155C-p97-FLAG-GFP, we 
analyzed the progression of the aggregates in the course of further cultivation of 
these cells. Interestingly, HEK293 cells overexpressing R155C mutant p97 exhibited 
significant delay in the rates in clearing the protein aggregates. After extended time, 
however, HEK293 cells overexpressing the mutant p97 also reduced the number of 
protein aggregates to levels found in the wt control.
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4.5. Role of p97 in the regulatory ERAD pathway
Immunoblotting of total cell lysates from untransfected and wt-p97 and R155C-p97 
transfected HEK293 cells under non-stressed and MG132 stressed conditions showed 
that i) the poly-ubiquitination of proteins seem to be disturbed in R155C mutated 
p97. ii) The protein expression of Ufd1 appears to be reduced in mutant p97. iii) 
HMG-CoA reductase being not detectable in the case of mutated p97 could be 
explained by either a defect in its stabilization, or due to lack in the induction of its 
transcription. iv) The second hypothesis can be underlined by the findings that the 
COPII coat protein Sec24 also was not detected in R155C mutated p97 which leads 
to a defect in the translocation of the complex composed of SREBP (sterol regulatory 
element-binding protein) and SCAP (SREBP-cleavage-activating protein) and thus
their activation in the GOLGI, and finally the observation that v) SCAP was found 
downregulated in these mutated cells under stress conditions. 
Some of the proteins involved in this pathway are selectively driven to proteasomal 
degradation via the ERAD pathway, which is done through poly-ubiquitination 
followed by processing to the proteasome, or are protected against degradation via 
selective binding to poly-ubiquitination inhibiting compounds. For many of the 
protein-protein interactions in this regulatory pathway cholesterols and cholesterol 
like compounds were identified as mediators for their binding (Song et al., 2005; Sun 
et al., 2005; Bengoechea-Alonso and Ericsson, 2007). Our in silico findings showed 
a putative interaction of p97 with a sterol compound which may be disrupted by the 
R155 mutations. For the R155C mutated p97 we could show that components of the 
sterol dependent HMGR homeostasis pathway and HMGR itself are significantly 
missregulated. Thus, it is not unlikely to speculate that a sterol dependent complex 
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formation of p97 and other components is disturbed. Finally, this would lead to a 
disrupted ERAD function and degradation-prone proteins could accumulate.
These findings are underlined by our analysis of the proteasomal activity. HEK293 
cell extracts enriched in proteasomes were used to quantify the proteasomal activity. 
Here, overexpression of p97 increased the proteasomal activity compared to non-
transfected HEK293 cells. In contrast, cells overexpressing R155C mutated p97 
indicated a marked inhibition of all three major proteasomal activities. In a recent 
study, Kobayashi et al. (2007) report on p97 being involved in the re-solubilisation 
process of abnormal protein aggregates. Thus, the protein aggregates induced by 
MG132 treatment may be accessible for degradation in both wt and mutated p97 
overexpressing cells. However, the marked delay in the aggregate clearance of cells 
overexpressing p97 mutant protein may be attributed to a disturbed proteasomal 
function. In line with reports indicating a close relation of proteasomal activity and 
autophagy, our findings further indicate that the downregulation of proteasomal 
acitivity is coupled to an upregulation of autophagic processes in IBMPFD (Brodsky 
and Scott, 2007; Ding et al., 2007; Pandey et al., 2007; Rubinsztein, 2007).
4.6. Outlook
In the field of known p97 cofactors, there should be a good chance to find additional 
pathways where mutated p97 is involved. Therefore, GST pull down experiments 
with special emphasis on the differences between wt- and mutated p97 protein will 
be performed together with total cell lysates of cultured cells and with patient 
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material. In addition, these pull down experiments should be performed in the 
presence of the putative small molecule ligands found in our in silico analysis. 
To analyse the interaction of p97 with these potential ligands, as an alternative assay 
to gas chromatography coupled to mass spectrometry, isothermal calorimetry will be 
performed.
Furthermore, the morphological and biochemical characterization of the sequential 
steps of the progressive IBMPFD muscle pathology should be analyzed in more 
detail. Therefore a p97 R155C knock-in mouse model is in progress. Here, special 
emphasis should be placed on the comparison of pathological findings in human and 
murine IBMPFD muscle tissue, too.
The effects of the R155C-VCP mutant on the ubiquitin proteasome pathway shown 
in this work will be further analyzed in other cell culture models and in material from 
biopsy of human IBMPFD muscle and, once it is available, in mouse muscle.
RNA-microarray and proteome analysis of IBMPFD muscle tissue derived from 
early disease stages may underline - beside other new findings - our results in the 
missregulated HMG-CoA reductase pathway. Some interesting components in this 
pathway, especially the ubiquitin ligase and deglycosidase gp78, are interesting 
compounds where a cholesterol-mediated interaction with p97 could be negatively 
influenced.
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5. Materials and Methods
Standard experimental protocols as well as standard buffer solutions are not given in 
this section; please refer to Molecular Cloning: A Laboratory Manual (Sambrook, J., 
Fritsch, E.F., and Maniatis, T.; Cold Spring Harbor Laboratory Press, NY, Vols. 1-3 
(1989)). Fine chemicals were from Sigma, unless indicated otherwise. Standard 
laboratory reagents were from local suppliers.
5.1. Mammalian Cell Culture
5.1.1. Culture conditions
HEK293 cells (ATCC: CRL-1573), C2F3 cells (subclone of C2C12, Clemen et al., 
1999; C2C12 ATCC: CRL-1772) and ΦNX-E (S. Kinoshita and G. Nolan, Stanford 
University, USA) were grown in Dulbeco’s modified Eagle’s medium containing 
4,5 g/l glucose (Sigma), supplemented with 10% fetal calf serum (FCS) (Biochrom), 
2 mM L-glutamine (Biochrom), 1 mM sodium pyruvate (Biochrom), 100 U/ml 
penicillin G and 100 µg/ml streptomycin (Invitrogen) in 5% CO2 at 37°C. 
Differentiation of C2F3 myoblasts was induced replacing the FCS by 1% horse 
serum. Normal and IBMPFD primary human myoblasts were grown in skeletal 
muscle cell growth medium (Promocell, Germany; C-23060 with supplement mix 
C-39365 added).
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5.1.2. Transfection methods
Transient transfection of HEK293 cells was carried out by electroporation 
(1x106 cells, 5 µg plasmid; 475 µF, 240 V, 4 mm cuvette). Stable HEK293 clones 
were obtained by selection with 1.2 mg/ml G418. Transient transfection of C2F3 
cells using Lipofectamine was done according to the instructions of the manufacturer 
(Invitrogen, Germany). Transient co-transfection of pDsRed2-ER, pDsRed-
Monomer-Golgi and pDsRed2-GAPDH in HEK293 cells stably overexpressing wt or 
mutant p97-GFP was carried out using FuGENE HD (Roche, Germany) according to 
the manufacturer’s guidelines.
For transduction of C2F3 cells, ΦNX-E cells were used to produce retrovirus 
particles. ΦNX-E cells were seeded at 2 x 106 cells in 60 mm dishes and transfected 
the next day using a calcium phosphate transfection protocol (Ausubel et al., 1998). 
48 and 72 hours post transfection retroviral supernatant was collected, centrifuged to 
pellet cell debris, filtered through a 0,45 µm filter and used for infection of target 
cells according to Springer and Blau (1997). Target C2F3 cells were seeded at 1.5 x 
105 per 60 mm dish at 24 hours prior to transduction. The distribution of the fusion 
protein was analyzed by indirect immunofluorescence and immunoblotting using 
antibodies directed against p97 and the FLAG epitope. 
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5.1.3. Generation of growth curves
Proliferation rates of stably transfected p97-GFP HEK293 cells, untransfected 
control HEK293 cells, and transduced and untransduced C2F3 cells were obtained by 
seeding cells at a density of 1 x 106 cells / 60 mm dish in triplicate. After 24 h cells 
were trypsinized and counted again using a Neubauer counting chamber.
5.1.4. Cell stress experiments
To induce a stress response in cultured cells, various drugs and conditions were used. 
MG132 (Calbiochem, USA; 10 mM stock in DMSO; 5 µM final concentration, 16h; 
Kitami et al., 2006; Weihl et al., 2006), Clasto-Lactacystin ?-Lactone (Calbiochem; 
10 mM stock in DMSO; 10 µM final concentration, 24 h; Steinhilb and Gaut, 2001; 
Waelter et al. 2001), Wortmannin (Calbiochem, datasheet 681675; 1 mM stock in 
DMSO; 1 µM final concentration, 22 h), H2O2 (Sigma, Germany; 400 µM final 
concentration, 16 h; Ardley et al. 2003) were added to the normal growth medium. 
Cells treated with MG132 were washed twice with PBS and further grown in fresh 
medium after 16 h of MG132 incubation. To cell cycle arrested cells (see cdk4 
inhibitor below) MG132 was added with a delay of 6 h. For osmotic shock 
experiments, cells were incubated in 150 mM urea dissolved in normal culturing 
medium (Sigma, Germany; D’Alessandro et al., 2002) for 5 min. The solution was 
changed to fresh medium and cells were subsequently fixed after 4 min. UV-B 
irradiation experiments (total dose of 100 J/m2 at a wavelength of 254 nm) were 
performed placing opened culture dishes containing a minimal volume of PBS in an 
UV-crosslinker (Hoefer UVC 500, Amersham Pharmacia Biotech, Germany; 
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Westfall et al. 2005). Cells were further incubated in fresh medium and analyzed 
after 12 h. Mitomycin C treatment (medac, Germany; 10 µg/ml final concentration; 
standard protocol) was done for 3 h in normal culturing medium followed by two 
washing steps with PBS. Cells were subsequently analyzed after 1, 7 and 14 days. 
For continuous cell cycle arrest in G1 phase a CDK4 inhibitor (2-Bromo-12,13-
dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione; Calbiochem; 1 mM 
stock in DMSO; 200 nM final concentration; Zhu, G. et al., 2003) was added to the 
growth medium as indicated in the Results section. Cells were either fixated in 
4% paraformaldehyde for microscopy or lysed in Laemmli buffer for Western 
blotting.
5.2. Imaging
5.2.1. Indirect immunofluorescence and imaging of living cells
Biopsies were fixed in 3% paraformaldehyde in a 0,2 M phosphate buffer, pH 7,4, 
for 2 h. After rinsing 5 times in 0,2 M phosphate buffer and PBS, the biopsies were 
infiltrated with saccharose at 12% and 18% to obtain a gradual substitution of saline 
solution with glucosate solution and then to avoid disruption of cellular membranes 
during successive phases. Finally, sections were frozen in liquid nitrogen.
Twenty-µm-thick sections were cut on a cryostat and collected on glass slides coated 
with 0,5% gelatin and 0,005% chromium potassium sulfate. To block nonspecific 
sites and to render the membranes permeable, sections were preincubated with 1% 
BSA and 0.3% Triton X-100 in PBS at room temperature for 15 min. Finally, 
sections were incubated with primary antibodies for 2 h. The first fluorochrome was 
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applied for 1 h after incubation with the primary antibody. For double-localization 
reactions, after 5 times rinsing with PBS and incubation with a biotinylated IgG in 
goat to obtain saturation of residual free binding sites, sections were incubated with a 
secondary antibody. Slides were finally washed in PBS and sealed with mounting 
medium. 
Cells were seeded on coverslips and grown to approx. 50 – 70% confluency, washed 
with PBS and subsequently fixed either in -20°C methanol for 10 min or in 
4% paraformaldehyde for 20 min followed by treatment with 0,5% Triton X-100 and 
PBS/Glycin 0,15% for 5 min each. Non-specific binding sites were blocked by 
incubating the cells twice for 15 min in PBG (0,5% BSA, 0,045% fish gelatine in 
PBS). Incubation with the primary antibody was performed at room temperature for 
2 h. After 5 washes in PBS/Glycin, 5 min each, cells were incubated for 1 h with 
secondary antibody at room temperature, washed 5 times in PBS/Glycin and 4 times 
in PBS, 5 min each, rinsed in water and embedded in Gelvatol (Langanger et al., 
1983).
Indirect immunofluorescence analysis as well as examination of living cells was 
done using a confocal laser scan microscope (Leica DM-IRBE; Leica, Germany).
5.2.2. Fluorescence protein protection (FPP) assay
The fluorescence protein protection (FPP) assay was performed as described by 
Lorenz et al. (2006). Cells were fixed for microscopic analysis. Double transfected 
HEK293 cells (wt- or R155C-p97-GFP plus pDsRed2-ER, pDsRed-Monomer-Golgi 
or pDsRed2-GAPDH, respectively) were either directly fixed using 
4% paraformaldehyde or first treated with 20 µM digitonin for 1 min followed by 
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4 mM trypsin for 5 min, both dissolved in KHM buffer (110 mM potassium acetate, 
20 mM HEPES, 2 mM MgCl2)
5.3. Gel electrophoresis and Western blotting 
Gel electrophoresis and Western blotting of cultured cells were performed according 
to standard protocols (Sambrook, J., Fritsch, E.F., and Maniatis, T.; Cold Spring 
Harbor Laboratory Press, NY, Vols. 1-3 (1989))
For one- and two-dimensional gel electrophoresis, SDS-PAGE, protein transfer and 
visualization of muscle biopsies were carried out according to Clemen et al., 2005. 
5 mg of human skeletal muscle specimen were pulverized by a pestle at ???°C, 
suspended on ice in 200 ??? ?????? ??????? ??? mM HEPES–NaOH, pH 7.0, 1 mM 
PMSF, 1 mM EDTA, complete mini protease inhibitor(Roche)), homogenized 1 min 
by sonification on ice (Sonifier UP200S dr. hielscher) and centrifuged for 1 min at 
1000 × g. 100 ?????????????????????????????????????????? at 125.000 × g for 20 min 
at 4°C. The resulting pellet was resuspended in 200 ??? ??????????????????????????????
centrifuged again. The first supernatant and the remaining pellet of each sample were 
adjusted to equal volume with lysis buffer and used for 1D-SDS–PAGE and Western 
blotting analysis:
2D gel electrophoresis was performed according to Clemen et al., 2005 using an 
adaptation of the protocols described by Görg et al., Rabilloud et al. and the 
Amersham–Pharmacia Biotech protocol. 2 mg of each muscle specimen was cut at 
???°C, lysed in 200 ??? ?????? ??????? ??M urea, 2 M thiourea, 4% CHAPS, 40 mM 
Tris, 2% IPG-buffer, 2% DTT, 1 mM PMSF, protease inhibitor (Roche), 
bromophenol blue) at room temperature, homogenized and centrifuged at 16.000 × g 
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for 5 min. Samples of the supernatants were loaded with cups placed at the anodic 
and cathodic side of rehydrated 18 cm IPG-strips (pH 4–7 linear), focused at 22°C 
(Multiphor II horizontal) using the voltage gradient (power supply EPS 3501XL; 
50 kVh) linearly increased on 400 V during 30 min, followed by 400 V for 4 h, 
linearly increased on 3500 V during 5 h, followed by 3500 V for 12.5 h. The strips 
were briefly rinsed in H2O and prepared for the second dimension by a two-step 
equilibration and cysteine alkylation process. The strips were incubated two times in 
equilibration buffer (Tris/HCl 50 mM, pH 8.8; 6 M Urea; 30% v/v glycerol; 
bromophenol blue) for 12 min, in which 4% (w/v) iodoacetamide was added.
Subsequently, the strips were loaded on SDS gels (12.5% acrylamide) containing a 
small stacking gel according to Laemmli. Molecular weight standards were applied 
on a piece of filter paper positioned next to the basic end of the strip. Electrophoresis 
was carried out on a Hoefer SE 600 system at 20°C for which the current was limited 
to 25 mA per gel. Indirect immunoblotting was performed to standard protocols.
5.4. p97-cDNA, site-directed mutagenesis and plasmids:
Human wt-p97 cDNA was amplified by PCR, adding restriction sites, and a FLAG-
tag at the 3’ end. Therefore the following primers were used: hVCPfullExpF 5’-cggg 
atccaagcttcggccaccatggcttctggagccgattcaaaaggtgatgacctatcaa-3’ and hVCPfullExpR
5’-atagtttagcggccgcaggtacctctttatcgtcatcgtctttgtagtcgccatacaggtcatcatcattgtcttctgtgtat 
acactgccacctgtgc-3’. For amplification of an N-terminal, 208 amino acids spanning 
cDNA, the following primers were used adding restriction sites, and a FLAG-tag at 
the 3’ end: hVCPN208FLExpF 5’-cgggatccaagcttcggccaccatggcttctggagccgattcaaaa 
ggtgatgacc-3’ and hVCPN208FLExpR 5’-atagtttagcggccgcggtacctatttatcgtcatcg
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tctttgtagtcgccaccaatgtcatcataccctacttcattcaagg-3’. PCR-products were cloned in 
pGEMTeasy vector (Promega, Germany). The mutations R93C, R155H, and R155C 
were introduced using the site-directed mutagenesis kit (BD Biosciences, USA). The 
following primers were used: R93C-ivm 5’- cctaggcgtacgcaaaggttattcc-3’, R155C-
ivm 5’- catcccacc acagacaagaaaaatg-3’, R155H-ivm: 5’- catcccaccatggacaagaaaaatg-
3’, and Select-ivm-rev: 5’- cgaagaacgatatccaatgatgagc-3’ (changes an XmnI 
restriction site to EcoRV restriction site in the pGemTeasy vector for selection). 
Before further use plasmids were confirmed by restriction analysis and direct 
sequencing (Perkin-Elmer Cetus, USA). For transfection, the p97 cassettes were 
cloned into the pEGFP-N1 and pEGFP-C1 vectors (Clontech, USA). For viral 
transduction the cDNAs were cloned into the pBMN vector (pBMN-Z lacking the 
LacZ; S. Kinoshita and G. Nolan, Stanford University).
pDsRed2-ER and pDsRed-Monomer-Golgi were from Clontech (pDsRed2-ER 
vector No. 632409; pDsRed-Monomer-Golgi No. 632480; Clontech, USA). 
pDsRed2-GAPDH was obtained by cloning the GAPDH sequence from a 
GAPDH-CFP vector (GeneCopoeia, USA) C-terminally to DsRed2 into a pDsRed2 
vector (Clontec, USA).
5.5. Generation of mouse targeting vector
The homology arms of the targeting vector and the cDNA fragments to be used as 
southern probes have been amplified by PCR using BAC-clones RPCI23-124L1 and 
RPCI24-186I11 as templates. For the 5’ southern probe, the following primers where 
used: VCPsou5F 5’-ggccagtttccctatgttg-3’, VCPsou5R 5’-ggtggtcagtatct 
attaggtcta-3’, VCPsou3F 5’-atatgccaccatgcccatctaaaag-3’ and VCPsou3R 5’-cttgagtt 
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ggagagatgactcagcg-3’. The amplified PCR products were cloned into the 
pGEMTeasy vector. For generation of the knock-in vector, fragments were amplified 
using the following primers: VCParm1F 5’-gagcggccgcgtta 
actttccggctttcttttgccatttttcttgcagtg-3’ and VCParm1R 5’-ttttccttttgcggccgcaatac 
aagtgcaattagaggtgtcaagtacaggaccagaaac-3’ for homology arm 1 and 
VCParm2R155HF 5’- aaaaggaaaaggccggccggtaccgctttgtattataggagatatttttcttgtcca 
tggtggg-3’ and VCParm2His6F 5’-aaaaggaaaaggccggccggtaccgctttgtattataggaga 
tatttttcttgtccatcatcatcatcatcatggtgggt-3’ for the homology arm 2. In between both 
fragments the neo cassette was cloned and subsequently the resulting fragment was 
cloned into the pRapidFlirt vector. The R155C-p97 mutation was introduced by in 
vitro mutagenesis using the primer VCPmut155H-Cgenomisch 
5’-ggagatatttttcttgtctgtggtgg gatgcgtgctgtgg-3’.
5.6. Histological analysis
Cryostat sections (6 µm) from human skeletal muscle were stained by standard 
diagnostic techniques. Cardiac autopsy material from patient II was taken from the 
left and right ventricular and septal walls at the base, mid-cavity, and apical levels, 
and from the left atrial free wall. Sections of paraffin embedded material were 
stained by standard diagnostic techniques.
5.7. Antibodies
The following primary antibodies were used: polyclonal VCP/p97 rabbit antiserum 
(kind gift of Dr. Chou-Chi Li, National Cancer Institute at Frederick, Maryland, 
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USA); monoclonal mouse anti-VCP/p97 (Affinity BioReagents, USA); monoclonal 
anti-VCP (BD Biosciences, USA); monoclonal mouse antibody raised against 
ubiquitin (Novocastra, UK); rabbit anti-ubiquitin polyclonal antibody (Stressgen, 
Canada); rabbit anti-ubiquitin polyclonal antibody (DAKO, Denmark); monoclonal 
mouse anti-poly-ubiquitin, clone FK2 (Stressgen, Canada); mouse monoclonal anti-
desmin antibody D33 (DAKO, Denmark); rabbit polyclonal anti-αB-crystallin 
antiserum (Chemicon, USA); mouse monoclonal antibody raised against Ufd1 
(Transduction Laboratories, USA); mouse monoclonal antibody raised against Ufd1 
(BD Biosciences, USA), mouse monoclonal antibody raised against GST (Amersham 
Biosciences, Germany); mouse monoclonal anti-His antibody (Qiagen, Germany); 
mouse monoclonal anti-FLAG M2 antibody (Stratagene, USA); rabbit polyclonal 
enterokinase cleavage site (FLAG) antibody (Novus Biologicals, USA); TRITC-
Phalloidin (Sigma, Germany); monoclonal mouse antibody specifically recognizing 
GFP (Noegel et al., 2004), monoclonal mouse anti-SCAP antibody (Santa Cruz, 
USA), polyklonal rabbit anti HMG CoA reductase antibody (upstate, USA). Isotype 
specific secondary antibodies conjugated with FITC, Cy3, or Texas Red, and 
Alexa568 were applied according to the recommendations of the manufacturers 
(Southern Biotechnology Associates, USA; Jackson Immunoresearch Laboratories, 
USA; Molecular Probes, USA). Alternatively, sections incubated with anti-VCP and 
anti-ubiquitin antibodies were incubated with biotinylated secondary antibodies and 
the avidin-biotin complex. Visualization was performed with 3,3 diaminobencidine 
or the APAP-complex as reagent.
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5.8. Protein purification
E. coli strain BL21 expressing p97-GST constructs (wt, R93C, R155C or R155H) 
(kind gift of A. Böddrich after cloning our p97 cassettes into pGEX-6-P1-Vector) 
were grown in 250 ml LB-Medium at 37°C until OD600=0,8 followed by growing at 
RT till OD600=1,0. Protein expression was induced by 0,1 mM IPTG and further 
incubating overnight at RT. Cells were centrifuged at 800 x g and washed once with 
TE-buffer. For cell lysis, the pellet was incubated with 10 ml lysis buffer (20 mM 
Tris-HCl pH 8,0, 100 mM NaCl, 2 mM EGTA, 2 mM Benzamidin, 4 mM DTT, 
2 mM EDTA, 0,5 mM PMSF, 19 µg/ml Aprotinin, 10 µg/ml Leupeptin, 100 µg/ml 
Lysozym) for 15 min on ice and sonified for 3 min. After centrifugation at 
20.000 x g for 30 min, the pellet was discarded and the supernatant incubated with 
150 ??? ??????????-Beads (Sigma, Germany; equibrillated 2x in lysis buffer before 
adding) for 1 h at 4°C, washed 8x with 500 µl washing buffer (20 mM Tris-HCl 
pH 8,0 and 300 mM NaCl; centrifugation at 800 x g for 1 min), and finally incubated 
with 250 µl PreScission protease cleavage Puffer (50 mM Tris-HCl pH 7,5, 150 mM 
NaCl, 1 mM EDTA, 1 mM DTT). The PreScission protease (Roche, Germany) 
cleaves the GST-tag and itself can be removed by its GST-tag. 12 µl (24 U) of the 
protease were added to the beads for 2 h at 4°C. Cleaved p97 protein was eluted 
followed by an additional elution step with 200 µl cleavage buffer for 15 min. The 
eluted p97 protein was incubated with 50 µl of freshly equilibrated glutathion-beads 
for 1 h at 4°C to remove contamination with free GST. After centrifugation, the 
buffer was changed to PBS buffer. and finally the protein was concentrated using a 
Centricon (5.000 MWOC; Millipore, Germany). Protein concentrations were 
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determined using the Bradford assay (BioRad, Germany) and aliquots of 200 pmol 
protein were stored at -20°C until usage.
5.9. Filter assay
Protein aliquots (p97 wt, R93C, R155C, R155H; 200 pmol each) were thawed on ice 
and centrifuged for 10 min at 16.000 x g. For negative control, BSA was used instead 
of the p97 protein. The potential ligands 16-α-Hydroxypregnenolone (Research Plus, 
USA) and 25-Hydroxycholesterol (Sigma, Germany) were dissolved in DMSO.  
20 nmol were added to the protein (100x excess), and incubated at 22°C for 1 h. 
Samples were centrifuged at 5.000 x g at 4°C using Millipore Ultrafree-MC NMWL 
10.000 Biomax 10 filters (Millipore, Germany). The flowthrough was kept for 
further analysis, the membrane bound protein-ligand complex was washed 4x with 
160 µl PBS supplemented with decreasing amounts of DMSO in each washing step 
(4,7%, 3%, 1,5%, 0%). To elute potentially bound ligands, the protein concentrate 
was incubated 2x for 5 min with 0,1% TFA in PBS and centrifuged. The flow 
through was kept for further analysis.
5.10. Proteasome assay
Stably transfected HEK293 cells overexpressing wt-p97-FLAG-GFP and 
R155C-p97-FLAG-GFP and untransfected control cells were grown in 140 mm cell 
culture dishes up to approx. 80% confluence. Cell were trypsinized, counted using a 
Neubauer chamber, and adjusted to equal cell numbers. Cells were pelleted at 
200 x g and lysed in 300 µl homogenization buffer (50 mM Tris-HCl pH 7.2 ,1 mM 
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EDTA, 100 mM KCl, 5 mM MgCl2, 2 mM ATP, 0.04% (v/v) Nonidet P-40), 
sonified and centrifuged at 1.000 x g for 10 min followed by 16.000 x g for 15 min. 
To the latter supernatant 10% v/v glycerol was added. For storage, samples were 
snap frozen in liquid nitrogen and stored at -80°C. Protein concentrations were 
determined using a protein assay according to manufacturers protocol (BioRad, 
Germany). In addition, immunoblotting with an antibody directed against β-actin 
was performed. For each measurement of the proteasomeal activity, 1,5 µg protein 
were added to a single well of a flat bottomed 96 well plate in reaction buffer 
(50 mM TrisHCl pH 8.0, 5 mM MgCl2, 5 mM ATP, 1 mM DTT) and adjusted to a 
total volume of 100 µl. Blank values were acquired by incubating 1,5 µg BSA 
instead of protein extracts. The peptides N-Suc-LLVY-7-amino-4-methylcoumarin-
(AMC) (150 µM, chymotrypsin-like activity), Z-ARR-AMC (200 µM, trypsin-like 
activity) or Z-LLE-7-AMC (100 µM, caspase-like activity) (all Calbiochem, 
Germany), respectively, were added to test the indicated proteasome activities. To 
differentiate the proteasome activity from other peptidase activities the irreversible 
proteasome inhibitors Epoxomicin (1 µM; Calbiochem; inhibits chymotrypsin-like 
activity; Meng et al. 1999) and Adamantaneacetyl-(6-aminohexanoyl)3-(leucinyl)3-
vinyl-(methyl)-sulfone (15 µM; Calbiochem; inhibits all three major peptidase 
activities; Kessler et al. 2001) were tested in a control experiment preincubating them 
with the proteasome extracts for 10 min at 37°C before adding the peptides. After 
incubation for 60, 70 and 80 min at 37°C, proteasomal activity was measured in a 
fluorescence microplate reader (Fluoroskan Ascent, Thermo Fisher Scientific, 
Germany) at 365 nm excitation and 460 nm emission. 
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5.11. Statistical analysis
Data are expressed as mean ± standard deviation (SD). Statistical comparisons were 
made using Student's t-tests (unpaired, two-sided, unequal variance). A difference 
was considered significant at a value of p < 0.05. 
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7. Abbreviations
BSA Bovine serum albumine
CDC48 Cell devision cycle protein 48
CDK4 Cyclin-dependent kinase 4
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate
DAPI 4',6-Diamidino-2-phenylindole
DMSO Dimethyl sulfoxide
DTT Dithiothreitol
EDTA Ethylenediamine-tetraacetic acid
EGTA Ethylene glycol-bis(?-aminoethyl ether)-N,N,N????-
tetraacetic acid
ER Endoplasmic reticulum
ERAD Endoplasmic reticulum associated protein degradation
FBS Fetal bovine serum
FTD Frontotemporal dementia
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HEK human embryonic kidney
HEPES N-(2-Hydroxyethyl)piperazine-N?-(2-ethanesulfonic 
acid)
HMGR HMG CoA reductase
(3-hydroxy-3-methylglutaryl-coenzyme A reductase)
IBM Inclusion body myopathy
IBMPFD Inclusion body myopathy accociated with 
Paget disease of the bone and frontotemporal dementia
Insig-1 Insulin-induced gene 1
IPTG ???????????-D-1-thiogalactopyranoside
NP-40 Nonidet P-40
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PDB Paget disease of the bone
PMSF Phenylmethanesulfonyl fluoride
PMSF Phenylmethylsulfonylfluorid
SCAP SREBP-cleavage-activating protein
SDS Sodium dodecyl sulfate
Sec24 Protein transport protein
SREBP Sterol regulatory element-binding protein
TFA Trifluoro acetic acid
Tris Tris (hydroxymethyl) aminomethane /
2-Amino-2-(hydroxymethyl)-1,3-propanediol
Ufd1 Ubiquitin fusion degradation protein 1
VCP Valosin containing protein
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8. Abstract
Mutations in the p97 (VCP, valosin containing protein) gene cause a late-onset form 
of autosomal dominant Inclusion Body Myopathy associated with Paget disease of 
the bone and Frontotemporal Dementia (IBMPFD). p97 is an ubiquitously expressed 
member of the AAA-ATPase family with a tripartite structure comprising an 
N-terminal domain (Cdc48) involved in ubiquitin-binding, and two central D1- and 
D2-domains which hydrolyse ATP. p97 assembles into functional hexamers with a 
central cylinder formed by the D-domains surrounded by the N-domains. p97 has 
been associated with a wide variety of essential cellular processes including the 
ubiquitin proteasome protein degradation system and along with its cofactors Udf1, 
Npl4, and Derlin-1 with the endoplasmic reticulum associated protein degradation 
(ERAD). 
In this work the pathological consequences of three heterozygous p97-mutations 
(R93C, R155H, R155C; located in the N-terminal Cdc48 domain of the p97 protein) 
on human striated muscle in vivo and in vitro are presented. IBMPFD skeletal muscle 
pathology is characterized by degenerative changes and filamentous p97- and 
ubiquitin-positive cytoplasmic and nuclear protein aggregates. Furthermore, mutant 
p97 leads to a novel form of dilatative cardiomyopathy with inclusion bodies. 
Pull-down experiments showed that all three p97 mutations do not affect the binding 
to Ufd1, Npl4, and ataxin-3. Structural analysis demonstrated that R93 and R155 are 
both surface-accessible residues located in the center of cavities that may enable 
ligand binding. The search for putative ligands to the R93 and R155 cavities resulted 
in the identification of cyclic sugar compounds and a sterol-like compound providing 
a novel link to p97 carbohydrate and sterol interactions in the complex pathology of 
IBMPFD. Analysis of stably transfected HEK293 cells showed a significantly 
decreased proteasome activity for cells overexpressing mutated R155C-p97 and a 
prominent upregulation of its autophagic activity. The R155C-p97 overexpressing 
HEK293 cells also showed a significant delay in clearing aggregates induced by 
proteasome inhibition. Immunoblotting of cell lysates derived from proteasome 
inhibited HEK293 cells and after the reactivation of its proteasomal activity pointed 
to a missregulation of the cholesterol homeostasis pathway in HEK293 cells 
overexpressing mutated R155C-p97 indicating a disrupted ERAD function caused by 
R155C mutated p97.
Zusammenfassung
- 100 -
9. Zusammenfassung
Mutationen im p97 (VCP, valosin containing protein) Gen verursachen eine spät 
auftretende Form einer autosomal dominanten Einschlusskörper-Myopathie 
assoziiert mit der Paget-Erkrankung der Knochen und einer frontotemporalen 
Demenz (IBMPFD). p97 ist ein ubiquitinär exprimierter Vertreter der AAA-ATPase-
Familie mit einer dreiteiligen Struktur bestehend aus einer N-terminalen Domäne 
(Cdc48), welche in die Ubiquitin-Bindung involviert ist, und zwei zentralen D1- und 
D2-Domänen, welche ATP hydrolisieren. p97 lagert sich zu einem funktionalen 
Homohexamer zusammen, bestehend aus einem aus den D-Domänen gebildeten 
zentralen Zylinder, welcher von den N-Domönen umgeben wird. p97 wurde mit 
einer Vielzahl von essenziellen zellulären Prozessen in Verbindung gebracht, 
darunter das Ubiquitinin-Proteasom-Degradationssystem und einschließlich seiner 
Co-Faktoren Ufd1, Npl4 und Derlin-1 mit dem Endoplasmatischen Retikulum 
assoziierten Degradationssystem (ERAD).
In dieser Arbeit wurden die pathologischen Konsequenzen von drei heterozygoten 
p97-Mutationen (R93C, R155H und R155C; alle lokalisiert in der N-terminalen 
Cdc48-Domäne des p97 Proteins) anhand menschlicher quergestreifter Muskulatur in 
vivo und in vitro analysiert. Charakteristisch für die IBMPFD-
Skelettmuskelpathologie sind degenerative Veränderungen und filamentöse p97- und 
Ubiquitin-positive cytoplasmatische und nukleäre Proteinaggregate. Außerdem führt 
mutiertes p97 zu einer neuen Form der dilatativen Kardiomyopathie mit 
Einschlusskörperchen.
Pull-down Experimente konnten zeigen, dass alle drei p97-Mutationen keinen Effekt 
auf die Bindung mit Ufd1, Npl4 und Ataxin-3 haben. Strukturuntersuchungen 
zeigten, dass die Aminosäuren R93 und R155 frei zugänglich an der Oberfläche von 
p97 liegen. Beide bilden die Zentren von potentiellen Bindetaschen und könnten eine 
Ligandenbindung ermöglichen. Die Suche nach potentiellen Liganden für die R93 
und R155 Bindetaschen ergab verschiedene zyklische Zuckerverbindungen und ein
Sterol. Diese Ergebnisse eröffnen eine neue Verbindung zwischen p97 und einer 
Karbohydrat- und Sterol-Interaktion in der komplexen Pathologie der IBMPFD-
Erkrankung. Stabil transfizierte HEK239-Zellen zeigten eine signifikante Abnahme 
der Proteasom-Aktivität in R155C-p97 überexprimierenden Zellen und eine 
deutliche Zunahme von deren Autophagie-Aktivität. Außerdem zeigten diese 
R155C-p97 überexprimierenden HEK293-Zellen eine deutlich verzögerte 
Abbauaktivität von per Proteasominhibition induzierten Proteinaggregaten. 
Immunoblots von Zelllysaten aus Proteasom-inhibierten HEK293-Zellen und nach 
anschließender Proteasomreaktivierung wiesen auf eine Fehlregulation des 
Cholesterol-Homöostase-Signalweges für R155C-p97 überexprimierende Zellen hin. 
Dies impliziert eine gestörte ERAD-Funktion, verursacht durch die 
R155C-p97-Mutation.
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